Regulatory Guide 8.11: Difference between revisions

From kanterella
Jump to navigation Jump to search
(Created page by program invented by StriderTol)
(Created page by program invented by StriderTol)
Line 1: Line 1:
{{Adams
{{Adams
| number = ML15054A618
| number = ML003739450
| issue date = 06/30/2015
| issue date = 06/30/1974
| title = Applications of Bioassay for Uranium.
| title = Applications of Bioassay for Uranium
| author name = Sun C
| author name =  
| author affiliation = NRC/RES/DSA
| author affiliation = NRC/RES
| addressee name =  
| addressee name =  
| addressee affiliation =  
| addressee affiliation =  
| docket =  
| docket =  
| license number =  
| license number =  
| contact person = Karagiannis H
| contact person =  
| case reference number = RG 8.11
| document report number = RG-8.11
| document report number = DG-8054
| package number = ML15054A611
| document type = Regulatory Guide
| document type = Regulatory Guide
| page count = 11
| page count = 31
}}
}}
{{#Wiki_filter:U.S. NUCLEAR REGULATORY COMMISSION
{{#Wiki_filter:
Ju ly 2015 OFFICE OF NUCLEAR REGULATORY RESEARCH
Revision 1 REGULATORY GUIDE
  Technical Lead Casper Sun Written suggestions regarding this guide or development of new guides may be submitted through the NRC's public Web site under the Regulatory Guides document collection of the NRC Library at http://www.nrc.gov/reading
-rm/doc-collections/reg
-guides/contactus.html
.  Electronic copies of this regulatory guide, previous versions of this guide, and other recently issued guides are available through the NRC's public Web site under the Regulatory Guides document collection of the NRC Library at http://www.nrc.gov/reading
-rm/doc-collections/
. The regulatory guide is also available through the NRC's Agencywide Documents Access and Management System (ADAMS) at http://www.nrc.gov/reading
-rm/adams.html,  under ADAMS Accession No. ML15054A618. The regulatory analysis may be found in ADAMS under Accession No. ML14133A612 and the staff responses to the public comments on DG
-8054 may be found under ADAMS Accession No. ML15014A269.


REGULATORY GUIDE  
==A. INTRODUCTION==
8.11 (Draft was issued as DG
Section 20.108, "Orders Requiring Furnishing of Bioassay Services," of 10 CFR Part 20, "Standards for Protection Against Radiation," states that the Atomic Energy Commission may incorporate in any license provisions requiring bioassay measurements as necessary or desirable to aid in determining the extent of an individual's exposure to concentrations of radioactive material.
-8054, dated September 2014APPLICATIONS
 
OF BIOASSAY FOR URANIUM 
As used by the Commission, the term bioassay includes in vivo measurements as well as measurements of radioactive material in excreta. This guide provides criteria acceptable to the Regulatory staff for the development and implementation of a bioassay program for mixtures of the naturally occurring isotopes of uranium U-234, U-235, and U-238. The guide is programmatic in nature and does not deal with labora tory techniques and procedures.
 
Uranium may enter the body through inhalation or ingestion, by absorption through normal skin, and through lesions in the skin.  However, inhalation is by far the most prevalent mode of entry for occupational exposure.
 
The bioassay pro gram described in this guide is applicable to thi inhalation of uranium and its compounds, but does not include the more highly transportable compounds UF 6 and U0 2 F 2.  Significant features of the bioassay program devel oped in this guidb ar listed below: 1. A bioassay program is necessary if air sampling is necessary for purposes of personnel protection.
 
The extent of the bioassay program is determined by the magnitude of air sample results.
 
2. A work area qualifies for the "minimum bioassay program" so long as the quarterly average of air sample results is <1% of the Derived Air Concentration (DAC) and the maximum used to obtain the average is <25% of USAEC REGULATORY  
GUIDES Regulatory Guides we issued to describe and make available to the public rnelhods acceptable to ite AEC Regulatory staff of impmenmeting specific parts of the Cominrnstion's regulations, to delineate lechniques, -ed by the Staff in Ielliusting specific problems or postulated accidents.
 
or to provide guidance to aplitants Reglatory Guides ore not substitutes for regulations and complianci with them is not required.
 
Methods and solutions different from thoKi at set nm the guidlsl will be acscaptable if they provide a basts for the findings requisite to the iesuance or continuance of a permit or by the Commission.
 
Published will be revised periodicalt-.i at apropr~ate, to accommodatei commnrs amtd to relfle new information or experience.
 
June 1974 GUIDE DAC. It must be demonstrated that air sample results used for this purpose are representative of personnel exposure.
 
3. Under the minimum program, bioassays are per formed semiannually or annually for all workers to monitor the accumulatior&#xfd;
of uranium in the lung and bone. More frequent bioassays are performed for a sample of the most highly exposed workers as a check on the air sampling program; these bioassays are per formed at sufficient frequency to assure that a signifi cant single intake of uranium will be identified before biological elimination of the uranium renders the intake undetectable.
 
4. If a work area does not qualify for the minimum program, bioassays in addition to the minimum program are performed at increasingly higher frequencies, de pending on the magnitude of air sample results.
 
5. A model is used which correlates bioassay measure ment results with radiation .dose or with uptake of uranium in the blood (chemical toxicity). 
6. Actions are specified, depending upon the dose or uptake indicated by bioassay results. These actions are corrective in nature and are intended to ensure adequate worker protection.
 
7. Guidance is referenced for the difficult task of determining, from individual data rather than models, the quantity of uranium in body organs, the rate of elimination, and the dose commitment.
 
This bioassay program encourages improvement in the confinement of uranium and in air, sampling tech niques by specifying bioassays only to-ihe extent that confinement and air sampling can not be entirely relied upon for personnel protection.
 
C*0vPp of piutiishedguidtosmay be obtained by requet indicating the divisions testirend to the US. Atomic Energy Condmmd.on Washington D.C. Attention.
 
Director of Regulatory Stan<erde.
 
Comments and sugestions for irorsrovesents in t hes guides ae encouraged and Should be sent to the Secretary of the Commetuon, US. Atomic Energv Commission Wahington, D.C. 20545.  Attention:
Chief Public Proceedings Staff.  The uide* are issued in the following ten broad divisions:
1. Power Reactors 6. Products 2. A emrch and Test Reactors
 
===7. Transportation ===
3. Fuels med Materials Facilities
8.
 
Health 4. Enronmental and Siting 9, Antitrust Review S. Meegesair and Plant Protection
10. General U.S. ATOMIC ENERGY COMMISSION
REGULATORY
DIRECTORATE
OF REGULATORY
STANDARDS
REGULATORY
GUIDE 8.11 APPLICATIONS
OF BIOASSAY FOR URANIUM
 
==B. DISCUSSION==
The topics treated in this guide include determining
(1) whether bioassay procedures are necessary, (2) which bioassay techniques to use and how often, (3) who should participate, (4) the action to take as based on bioassay results, and (5) the particular results which should initiate such action. Taken together, these topics comprise an exposure control program. Technical bases for the criteria appearing in the guide are provided in "Applications of Bioassay for Uranium," WASH-1251, which is available from the Superintendent of Docu ments, U.S. Government Printing Office, Washington, D.C. 20402.  After an exposure to uranium has occuired, the difficult problems of estimating the quantity present in the body and the anticipated dose commitment arise.  This subject is treated in considerable detail in WASH 1251.  C. REGULATORY
POSITION !. Special Terminology Several of the terms used in this guide have been given special definitions and are listed in this section for the convenience of the reader.  Bioassay -The determination of the kind, quantity or concentration, and location of radioactive material in the human body by direct (in vivo) measurement or by analysis of materials excreted or removed from the body.  Derived Air Concentration (DAC) -- Equivalent to the concentrations listed in Appendix B to 10 CFR Part 20.  Dowe Commitment (Dc) -- The total radiation dose equivalent to the body or specified part of the body that will be received from an intake of radioactive material during the 50-year period following the intake.  Exposure -The product of the average concentration of radioactive material in air and the period of time during which an individual was exposed to that average concentration (jICi-hr/cc). 
Intake -The quantity of radioactive material entenng the nose and/or mouth during inhalation;
the product of the exposure and the breathing rate.  In Vivo Measurements
-Measurement of gamma or X-radiation emitted from radioactive material located within the body, for the purpose of estimating the quantity of radioactive material present.Maximum Permissible Annual Dose (MPAD) The annual maximum occupational radiation dose recommended by the ICRP for the body or part ul' the body.  Maximum Permissible Dose Commitment (MPDc) A dose commitment numerically equivalent to the Maximum Permissible Annual Dose.  Measurement Sensitivity Limit The smallest quan tity or concentration of radioactive material that can be measured with a specified degree of accuracy and precision.
 
Nontransportable- Slowly removed from the pul monary region of the lung by gradual dissolution .in extracellular fluids, or in particulate form by translocation to the GI tract, blood, or lymphatic system; Class (W), nontransportable dust with 50-day biological half-life in the lung. Class (Y), nontransportable dust with 500-day biological half-life in the lung.  Transportable- Dissolved upon contact with extra cellular fluids and translocated to the blood- Class (D), transportable dust with rapid clearance from the lung.  Uptake -- The quantity of radioactive material enter ing the nose and/or mouth during inhalation that is not exhaled and enters extracellular fluids.  w/o U-235 Percentage by weight of the isotope U-235 in a mixture of U--234, U-235, and U-238 (w/o U-235 in natural uranium is 0.72).  2. Programmatic Guidance The following programmatic guides are applicable where personnel are occupationally exposed to uranium in respirable form and in sufficient quantity that measurements of uranium concentrations in air are considered to be necessary for the protection of workers in ccmpliance with Regulatory requirements, including license conditions.
 
a. Basic Requirements and Minimum Capabilities The following guides establish basic requirements and minimum capabilities which should he found in a program for protection against internal exposure from operations with uranium: (1) Responsibilities foi protection against ura nium contamination should be weil defined and under stood by all personnel concerned and should be specified in direct;ves from management
(2) A comprehensive and technically sound protec tion program should be developed and implemented.
 
8.11-2 L I
(3) Personnel, space, equipment, and support resources should be provided as necessary to conduct the program.
 
(4) An effective method of periodic internal audit of the protection program should be maintained.
 
(5) Before assigning employees to work in an area where exposure to uranium contamination may occur, action should be taken to ensure that facility and equipment safeguards necessary for adequate radiation protection are present and operable, that the employees are properly trained, that adequate procedures are prepared and approved, that an adequate surface and air contamination survey capability exists, that a bioassay program at least equivalent to the program described in this guide will be maintained, and that survey and bioassay records will be kept.  b. Bioassay Program In the development of a bioassay program the following guides should be implemented:
(1) Necessity The determination of the need for bioassay measurements should be based on air contamination monitoring results in accordance with criteria contained in this guide.  (2) Preparatory Evaluation Before assigning an employee to work in an area where substantial exposure to uranium contami nants may occur, his condition with respect to radio active material of similar chemical behavior previously deposited and retained in his body should be determined and the necessity for work restrictions evaluated.
 
(3) Exposure Control The bioassay program should include, as appro priate, capabilities for excreta analyses and in vivo measurements, made separately or in combination at a sufficiently high frequency to assure that engineered confinement and air and surface contamination surveys are adequate for employee protection.
 
The program should include all potentially exposed employees.
 
(4) Diagnostic Evaluation The bioassay program should include capabili ties for excreta analyses and in vivo measurements as necessary to estimate the quantity of uranium deposited in the body and/or in affected organs and the rate of elimination from the body and/or affected organs.3. Operational Guidance a. Criteria for Determining the Need for a Bioasay Program Where air sampling is required for purposes of occupational exposure control, bioassay measurements are also needed (Table 1) The bioassay frequency should be determined by air sample results as averaged over I quarter.
 
Testing should be performed to determine whether awi sampling is representative of personnel exposures.
 
Air sample results which have been verified as representative may be used to determine the quarterly average.
 
If the 1-quarter average does not exceed 10% of the appropriate Derived Air Concentration (DAC) from Appendix B to 10 CFR Part 20 and if the maximum result used in the calculation of the average does not exceed 25% of DAC, only a minimum bioassay program is necessary (Table 2). If the 1-quarter average exceeds 10% DAC, or if the maximum result exceeds 25% of the DAC, additional bioassays are necessary (Table 3), except as noted below. Frequency criteria for both cases are discussed in Section C.3.c. The approach is illus trated in Figure 1. The additional bioassays are not performed for a specific individual if the licensee can demonstrate that the air sampling system used to protect the individual is adequate to detect any significant intake- and that procedures exist for diagnostic bioassays following detection of an apparently large intake.  The necessity for bioassay measurements may also arise following an incident such as a fire, spill, equip ment malfunction, or other departure from normal operations which caused, or could have caused, abnor mally high concentrations of uranium An air. Criteria for determining this necessity are shown in Pigure 2. (The term "Early Information" refers to an instrumented air sampler with an alarm device.) Reliance cannot be placed on nasal swab results from mouth breathers.
 
bioassays should be performed.
 
Special bioassay measurements should be per formed to evaluate the effectiveness of respiratory protection devices. If an individual wearing a respiratory protection device is subjected to a concentration of transportable uranium in air within a period of I week, such that his exposure with no respiratory protection device would have exceeded 40 x DAC ,Ci-hr/cc, urinalysis should be performed to determine the result ing actual uranium uptake. If an individual wearing a 8.11-3 TABLE I SELECTION
OF BIOASSAY MEASUREMENT
TECHNIOUES
Transportable Non transportable Purpose Compounds Compounds Choice of Measurement
1st 2nd' 3rd Preparatory Evaluationb uc ivc fr u Exposure Control Check on Air Sampling Program u iv f u Monitoring of Lung Burden Buildup -iv f u Monitoring of Bone Burden Buildup u u Detection of Unsuspected Intake u iv f Diagnostic Evaluation u iv f u Work Restriction Removal i iv f u alf for any reason air sampling is not adequately effective, and the appearance of urinary uranium is long delayed by extreme nontransportability, the buildup of uranium in the lung pmay continue undetected until a positive in vivo result is obtained.
 
Fecal analysis is an excellent and highly recommended early indicator in such cases. Fecal analysis should be considered if in vivo measurements are too infrequent to permit early identification of an unfavorable trend.  bDiagnostic evaluation necessary if results are positive.
 
Cu, urinalysis;
f, fecal analysis;
iv. in vivo.respiratory protection device is subjected to a concen tration of nontranrsportable uranium in air within a period of 13 weeks, such that his exposure with no respiratory protection device would have exceeded 520 x DAC jiCi-hr/cc, the resulting actual uranium deposition in the lung should be determined using in vivo measurements and/or fecal analyses.
 
These special bioassay procedures should also be conducted if for any reason the magnitude of the exposure (with no respira tory protection device) is unknown.
 
b. Selection of Measurement Techniques The appropriate selection of bioassay techniques appears in Table 1. Preparatory evaluation refers to bioassays performed for job applicants or existing employees prior to an assignment involving potential exposure to uranium. Exposure control refers to bio assays performed to assure that engineered confinement and the air sampling program are sufficiently effective in the control and evaluation of exposures.
 
Diagnostic evaluation refers to bioassays performed following a known significant exposure.
 
These evaluations are per formed to determine the location and magnitude of uranium deposition, which would in turn aid in deter mining whether therapeutic procedures are indicated and whether work restrictions are necessary.
 
The evaluations would also aid in estimating the retention function and dose commitment.
 
Work restriction removal refers to bioassays performed for employees who, because of past depositions of radionuclides, have been restricted by management in their work involving exposure to radio active material until the magnitude of such depositions is reduced sufficiently to permit the removal of these work restrictions.
 
c. Selection of Measurement Frequency Acceptable frequencies for the minimum bioassay program are given in Table 24Table 3 gives acceptable frequencies when additianal bioassay measurements are necessary to detect unsuspected single intakes, unless the measurement capability is the limiting factor. Figures 3 through 7 present the maximum time between measure ments based on measurement sensitivity considerations;
the figures should be used to determine the measure ment frequency unless the interval specified in Table 3 is shorter. The Class (W) curve in Figure 5 may be used for Class (Y) materials if it is known that Class (D) or Class (W) materials are present.
 
Table 2 specifies, for the minimum program, semiannual or annual bioassays for monitoring the accumulation of uranium in the lung and bone, plus 8.11-4 TABLE 2 BIOASSAY FREQUENCY
FOR EXPOSURE CONTROL Program Objective Dust Measurement Frequency Classification Techniquea Check on air sampling (D) u Use Figures 3 and 4 program and on con- (W) iv Use Figure 6 finement procedures (Y) iv Semiannual Minimum" and equipment.
 
Adequate if Monitor lung burden (W) iv AnnualF QA < I/ I 0DA( buildup. (Y) iv Serruannualc and M < 1/4 DAC Monitor bone burden (D) u Semiannual buildup. (W) u Semiannual (Y) u Class (D) or Class (W) Not Present, Annuald (Y) u Class (D) or Class (W) Present, Semiannuald Additional Detect unsuspected (D) u Use Table 3e intake. (W) iv, f, or u Use Table 3 e Acceptable it (Y) iv, f. or u Use Table 3e QA > 1/10 DAC and/or M > 1/4 DAC aiv, n vivo; u, urinalysis;
f, fecal analysis.
 
bQA, quarterly average of air sample results; M, maximum result used to determine QA CThese frequencies are applicable if no individuals are near work restriction limits. Quarterly or even monthly iv may become necessary as workers approach these limits dSpecial urinalysis should be performed each time exposure to new Class (Y) material begins to determine if more transportable component is present.
 
eThese measurements are additional to those listed above for the minimum program. If it is demonstrated that air sampling provided for a specific individual is adequate to detect any sigmficant intake and that procedures exist for diagnostic bioassays following detection of an apparently large intake, these additional measurements need not be performed.
 
(00
TABLE 3 FAEQUENCYa FOR ADDITIONAL
BIOASSAYS
BASED ON CONCENTRATION
OR EXPOSURE QA Most recent quarterly average of concentration or most recent quarterly average of weekly exposures M Maximum result used in the calculation of the quarterly average u urinalysis iv -it vivo Multiply numbers in first column by DAC pCi/cc or by 40 DAC pCi-hr/cc.
 
Frequencies are given in bioassaysper year at equally spaced intervals.
 
Air Sample Results Class (D) Class(W) u U iv Class (Y) ub iv O<QA< 1/10 1/4<M< I I <M< 10 10<M I/i0<QA< 1/4 0<M< I I <M<10 10< M 1/4<QA< 1/2 C<M< I i<M< !0 ii < M 4 12 4 12 2c 4 12 12 26 1i2<QA< I 0<M< 10 10<M 2 4 12 2 4 12 4 12 26 26 52 1 2 4 1 2 4 2 4 12 12 12 2 4 12 4 12 26 12 26 52 26 52 2 2 4 4 4 4 4 12 12 12 a Low frcqucncic&#xfd;
indicated may be precluded by measurement capability limitations:
see Figures 3 through 7 bAppicable if Class (D) or Class (W) materials are known to be present;convert
52 and 26 to 12 if they are not present. Fecal analysis may be substituted for urinalysis.
 
c Frequency possible only for high w/o U-235; naturally occurring urinary uranium prohibits detection otherwise.
 
more frequent bioassays (based on measurement sensi tivity) to check on the air sampling program. Section C.3.d indicates that all workers should participate in the bioassay program for purposes of monitoring the organ buildup, while only a sample of workers is sufficient for checking the air sampling program. If a working area does not qualify for the minimum program, additional bioassays are specified in Table 3 at somewhat higher frequencies.
 
Any urinalysis procedure performed for one of these purposes may be used to satisfy a urinalysis requirement for another purpose, provided the fre quency criteria are met. A similar statement may be made regarding in vivo measurements.
 
The purpose of the additional bioassay measure ments is the timely detection of unsuspected exposures not detected by the air sampling program. Therefore, the additional bioassays are not necessary for an individual who is protected by a monitoring system that essentially assures detection of any significant intake.  Although fecal analysis is not shown in Table 3, this procedure is preferred over urinalysis for Class (W) and Class (Y) materials and may be substituted for urinalysis in the table. If in vivo measurements are made at the frequency shown for urinalysis, Class (W) and Class (Y), the unnalyses are unnecessary;
the urinalyses prescribed in Table 2 are adequate.
 
The bioassay measurement frequency, as deter mined from Table 2 or 3 (or the associated figures), should not be decreased because of consistently low bioassay results; bioassay measurements are needed as a final check on the contamination confinement capability and on the effectiveness of the air sampling program.
 
Consistently high bioassay results may suggest that more 8.11-6 frequent bioassays should be performed even though there is no such indication from air samples. In this case, however, improvements in the air sampling program are required rather than more frequent bioassays.
 
The appropriate frequency can be determined from air sample data if the air sampling program is adequately representative of inhalation exposures.
 
If workers are exposed to a mixture of uranium compounds, the DAC for the mixture, DACm, should be calculated as Dn= [i, f DACm Zi DAC 1]-I where DACi is the DAC for the ith compound and fi is a fraction representing the contribution of the ith com pound. The calculation of fi depends on the exposure mode. If the material is a mixture, fi is the activity fraction.
 
For exposure in more than one area, fi is the time fraction spent in the ith area. As an alternative DACm may be taken as the lowest DACi. As to the quarterly average for air samples, if the material is a mixture and exposure occurs in only one area, the quarterly average calculation, applicable to all workers in the area, should be performed as for non-mixtures, i.e., from samples characterizing conditions in the area. If exposures occur in several areas, the quarterly average for the mixture may be a time-weighted average for the individual, using ( arterly average air samples that characterize full-time conditions in each area. i.e., n QAm = 2 fi QAi i=l where QAi is the quarterly average for the ith area and fi is the time fraction of the quarter that the individual worked in the ith area. As an alternative, QAm may be taken as the highest QAi.  Figure 5 indicates that a urinalysis measurement sensitivity of about 0.7 pCi/I is required to detect the equivalent of I MPDc following a single exposure to Class (Y) materials with neither Class (D) nor Class (W) "'tracer" dusts present. To obtain this sensitivity, a chemical concentration procedure is necessary.


==A. INTRODUCTION==
Fecal analysis is recommended as an alternative, using the frequency schedule given for urinalysis.
Purpose  This regulatory guide (RG) describes methods that the staff of the U.S.


Nuclear Regulatory Commission (NRC) considers acceptable for the development and implementation of a bioassay program for monitoring the intake of mixtures of uranium isotopes (U
If work restrictions that have been imposed do not involve total exclusion from restricted areas, it is necessary to ensure that bioassay measurements made for the purpose of removing work restrictions are performed at least as frequently as would be required for purposes of exposure control.A monthly in vivo frequency may be reduced to quarterly if weekly fecal analyses are made, with an in vivo measurement at the end of the quarter. An in vivo measurement should be performed as soon as practicable if the excretion rate exceeds 7 pCi/day Class (Y) or 700 pCi/day Class (W). For lower results the following procedure should be followed.
-234, U-235, and U
-238) by occupational ly exposed workers. This RG applies to holders of special nuclear material licenses under Title 10 of the Code of Federal Regulations
(10 CFR), part 70, "Domestic Licensing of Special Nuclear Material
,"  (Ref. 1).       Applicable Rules and Regulations
  10 CFR 20.1204(a), "Determination of Internal Exposure" (Ref.


2), states that each licensee shall, when required under 10
Results from the first 4 weekly specimens should be plotted (semilog)  
CFR 20.1502, "Conditions Requiring Individual Monitoring of External and Internal Occupational Dose," take suitable and timely measurements of: (1)
against time, and a best fitting curve should be extrapolated to t = 0. thus obtaining an estimate of the initial excretion rate, (dP Idt)o, and the individual's half-lifel T. The dose commitment, Dc, should be estimated using these values with the following equation: Dc= 8.4 T2 [where T is in days and (dP/dt)o is in MOCt/day.
concentrations of radioactive materials in air in work areas, (2)
quantities of radionuclides in the body, (3) quantities of radionuclides excreted from the body, or (4)
combinations of these measurements.


10 CFR 20.1201(e), "Occupational Dose Limits for Adults," requires licensees to limit the soluble uranium intake by an individual to 10
The actions indicated in Table 4 should then be taken. This procedure should be repeated at the end of 8 weeks when results from 8 specimens are available.
milligrams per week in consideration of the chemical toxicity.


Related Rules and Regulations
At the end of the quarter D. should be evaluated using results from all 12 specimens.
  10 CFR 20.1703(i), "Use of Individual Respiratory Protection Equipment," allows for an estimated dose based upon an assumption that the concentration of radioactive material that is inhaled when respirators are worn is equal to the ambient concentration in air without respiratory protection divided by the assigned protection factor. This regulation requires that if the dose is later found to be greater than the estimated dose, the corrected value must be used; if the dose is later found to be less than the estimated dose, the corrected value may be used.


RG 8.11, Rev. 1, Page
If the indicated Dc is < 3 rems, the in vivo measurement may be considered unnecessary If the Dc indicated by the fecal data exceeds 3 reins, the in vivo measurement should be performed.
2  10 CFR 20.2202, "Notification of Incidents," sets forth the criteria for those events involving byproduct, source, or special nuclear material possessed by the licensee that require either immediate notification or notification within 24 hours.


10 CFR 20.2203, "Reports of Exposure, Radiation Levels, and Concentrations of Radioactive Material Exceeding the Constraints or Limits," sets forth the criteria for submitting a written report to the NRC on a reportable event.
A quarterly in vivo frequency may be reduced to semiannual if monthly fecal analyses are made, with an in vivo measurement at the end of 6 months If any result exceeds 7 pCi/day Class (Y) or 460 pCi/day Class (W). an in vivo measurement should be performed as soon as practicable.


10 CFR 20.2205, "Reports to individuals of exceeding dose limits," provides that when a licensee is required by 10 CFR 20.2203 or 2204 to send a report to the Commission of any exposure of an identified occupationally exposed individual, or an identified member of the public, to radiation or radioactive material, the licensee shall also provide the individual a report of the exposure data included in the report to the Commission.
For lower results the following procedure should be followed.


10 CFR part 70, "Domestic Licensing of Special Nuclear Material," establish es procedures and criteria for the issuance of licenses to receive title to, own, acquire, deliver, receive, possess, use, and transfer special nuclear material and provide for the terms and conditions upon which the Commission will issue such licenses.
Results from the first 3 specimens should be plotted (semilog)
against time, and a best-fitting straight line should be extrapolated to t= 0. Values for (dP /dt)o and T for the individual should be obtained and used in the above equation to estimate Dc. The actions indicated in Table 4 should then be taken. At the end of the fourth and fifth month, Dc should again be evaluated using results from all specimens.


Related Guidance RG 8.9, "Acceptable Concepts, Models, Equations, and Assumptions for a Bioassay Program" (Ref. 3), provides methods acceptable to the NRC staff for estimating intake of radionuclides using bioassay measurements.
At the end of the 6-month period, the in vivo measurement should be performed.


RG 8.22, "Bioassay at Uranium Mills" (Ref.
Fecal specimens used for this purpose should be obtained after 2 or more days of no exposure.


4), describes a bioassay program acceptable to the NRC staff for uranium mills (and applicable portions of uranium conversion facilities where the possibility of exposure to yellowcake dust exists), including exposure conditions with and without the use of respiratory protection devices.
In the extrapolation of excretion rate data to t= 0. it is necessary to ignore data points obtained for less than 2 days after exposure.


RG 8.25, "Air Sampling in the Workplace" (Ref.
d. Participation All personnel whose regular iob assignmentN
involve work in an area where bioassay ineasurernenI,, are required should participate in the bioassay program However, as long as air sainple results qualify the area and group of workers tor the minimum bioasssa program, special consideration may be given in the case 8.1 1-7 of bioassays obtained for the purpose of checking on the air sampling program, i.e., the first objective shown in Table 2. For these bioassays it is acceptable to limit participation to a representative sample of the group.  The sample should be composed of the most highly exposed or potentially exposed personnel and should include at least 10% of the workers who have regular job assignments in the area if the total number of such workers is 100 or more. If the total is between 100 and 10 workers, there should be 10 participants.


5), provides guidance on air sampling in restricted areas of the workplace.
If the total is less than 10 workers, all should participate.


RG 8.30, "Health Physics Surveys in Uranium Recovery Facilities" (Ref.
Thus, where the minimum bioassay program is being con ducted, all workers would participate either semi annually or annually for monitoring of uranium buildup in the lung or bone, in addition, those in the sample group would participate more frequently if required to do so by Figures 3, 4, or 6. (Note that the in vivo frequency for Class (Y) materials is semiannual in every case.) This sampling procedure will be of particular usefulness to those using Figure 4. Where bioassays in addition to the minimum program are conducted, all workers should participate (see Table 2, footnote e, for exception). 
Personnel whose duties involve only observance and who spend less than 25% of the work week in areas where bioassay is required may participate on a limited basis. The interval between bioassay measurements for such personnel should be a matter of judgement based on the magnitude of the exposure.


6), provides guidance on health physics surveys that are acceptable to the NRC staff for protecting workers at uranium recovery facilities (e.g., uranium mills, in
e. Action Based on Results Appropriate action as based on bioassay results is dependent first on the underlying purpose of the measurement.
-situ leach facilities, ion exchange recovery facilities, heap leach facilities) from radiation and the chemical toxicity of uranium.


RG 4.15, "Quality Assurance for Radiological Monitoring Programs (Inception through Normal Operations to License Termination)
(!) Preparatory Evaluation Where urinalysis for uranium is used to screen personnel prior to job assignment, the presence of any urinary uranium, as detected by routine laboratory procedures, should trigger an investigation.
-Effluent Streams and the Environment" (Ref. 7), provides quality assurance (QA) guidance on monitoring measurements that support the radiation and environmental protection programs.


The National Council on Radiation Protection and Measurements (NCRP) Report
Information regarding the location and quantity of uranium in the body should be sought, and conservative predictions as td future retention in the body should be made. This information can usually be derived from a review of the worker's previous exposure history, including previous bioassay results, and from subsequent bioassay measure mrents as necessary.
161, "Management of Persons Contaminated with Radionuclides" (Ref.


8), provides guidance for emergency treatment if a severe intake of uranium substances were to occur.
Findings should be compared with criteria given in Section C.3.f.(8), or with other accept able criteria, and a decision should be made to approve the job assignment if acceptable criteria are met, or to impose a delay otherwise.


RG 8.11, Rev. 1, Page
(2) Exposure Control When work is in progress, and bioassay mea surements are being made routinely, it is essential to ensure that the measurement results are carefully reviewed by qualified personnel and that appropriate action is taken if the results are considered high. Action should be based on the organ burden, the dose commit ment, or chemical damage to the kidney as indicated (however roughly) by the result. Appropriate actions are shown in Tables 4 and 5 for single intakes. In the case of chronic exposure, when bioassay results indicate that the organ burden is continuing to rise, action should be taken to assure that additional buildup will not interfere with the worker's career. When urinalysis indicates
3  Purpose of Regulatory Guides The NRC issues regulatory guides to describe to the public methods that the staff considers acceptable for use in implementing specific parts of the NRC's regulations, to explain techniques that the staff uses in evaluating specific problems or postulated accidents, and to provide guidance to licensees and applicants. Regulatory guides are not substitutes for regulations and compliance with them is not require d. Methods and solutions that differ from those set forth in regulatory guides will be deemed acceptable if they provide a basis for the findings required for the issuance
50% or more of the maximum permissible lung burden for nontransportable uranium, in vivo measurements should be undertaken.
, continuance or amendment of a permit or license by the Commission.


Paperwork Reduction Act This regulatory guide contains information collection requirements covered by 10 CFR part
Work restrictions should be tmposed without waiting for in vivo measurements if urinalysis indicates more than I permissible lung burden.  (3) Diagnostic Evaluation Diagnostic bioassay measurements are made to .estimate the quantity and distribution of radionuclides in the body after determination that a large deposition has occurred.
20 , "Standards for Protection Against Radiation," and 10 CFR part 70 "Domestic Licensing of Special Nuclear Material," that the Office of Management and Budget (OMB) approved under OMB control number s 3150-0014 and 3150
-0009, respectively. The NRC may neither conduct nor sponsor, and a person is not required to respond to, an information collection request or requirement unless the requesting document displays a currently valid OMB control number.


==B. DISCUSSION==
Actions to be based on diagnostic results include (I) selection of subsequent measurement tech niques and frequencies, (2) imposition or removal of work restrictions, (3) referral to a physician, and (4) the physician's decision to attempt acceleration of the nuclide elimination process.
Reason for Revision RG 8.11 was issued in June 1974 to provide guidance to NRC licensees on methods the staff found acceptable to demonstrate compliance with the then
-current version of NRC's radiation protection regulations in 10 CFR part
20. In a 1991 rulemaking (May 21, 1991; 56 FR 23360), the NRC promulgated amendments to its 10 CFR part 20 regulations, including a renumbering of those regulations. As such, this revision to the guide seeks to achieve alignment with the regulatory structure of
10 CFR part 20 by updating the guide's cro ss-references to the current 10
CFR part 20 regulations.


In addition, this revision identifies the bioassay interpretation methods described in NUREG/CR-4884, "Interpretation of Bioassay Measurement" (Ref.
f. Action Points This -section presents acceptable correlations be tween organ burden, dose commitment, or uranium uptake and the quantities actually measured using bioassay techniques, thus providing action point criteria for purposes of exposure control. Guidance is also given for work restrictions and for referral to a physician.


9) and RG 8.9, "Acceptable Concepts, Models, Equations, and Assumptions for a Bioassay Program," as being acceptable methods for the interpretation of bioassay data to estimate intakes and doses. This revision also approves for use certain sections of a voluntary consensus standard, namely, the American National Standards Institute/Health Physics Society (ANSI/HPS)
These correlations are derived entirely from models. This approach is acceptable for purposes of exposure control. However, these correlations would actually predict the dose commitment or uranium uptake only if the bioassay result was without error and if every condition of the models was actually achieved.
N13.22-2013 standard, "Bioassay Program for Uranium ," (Ref.1 0) as a means for licensees to demonstrate compliance with the NRC regulations
10 CFR 20.1201(e) and 10 CFR 20.1204(a). 
  Background This RG pertains to uranium bioassay programs in general; however, it does not address issues related to bioassay measurement techniques such as whole body counting and excreta bioassay sampling and measurements.


Specific information regarding uranium intake during mining (extracting natural uranium ore from the earth) and milling (leaching uranium from the ore and concentrating it to produce yellowcake, including UO 2 F 2, ammonium diuranate ((NH
(1) Dose Commitment and Uptake Correiations, Single Intake, Class (D) Dust The correlation between dose commitment to the bone and urinary uranium concentration is shown in Figure 8 for Class (D) materials.
4)2 U 2 O 7), uranyl peroxides (UO
4*n H 2O), and uranium trioxide (UO 3)) can be found in RG 8.22, "Bioassay at Uranium Mills."


RG 8.11, Rev. 1, Page
In the right hand margin of the figure the recommended actions, from Table 4, are indicated.
4  Licensee determinations regarding participation in the uranium bioassay program should be based on estimates of the type and quantity of intakes that may occur using procedures that are expected to take place at each facility during the monitoring year. The program is confirmatory in that low or zero results may indicate that the measures in the workplace to control uranium materials are effective
, and that no unexpected intakes have occurred. Based on operational experience, licensees may be able to justify adjustments in their bioassay program, such as a reduction in bioassay routine monitoring frequency, the inclusion of fewer workers in the bioassay program, or licensees may seek an alternative bioassay program.


Harmonization with International Standards The NRC has a goal of harmonizing its guidance with international standards, to the extent practical. The International Commission on Radiological Protection (ICRP) and the International Atomic Energy Agency (IAEA) have issued a significant number of standards, guidance and technical documents, and recommendations addressing good practices in most aspects of radiation protection. The guidance of this RG is generally consistent with the guidance in the following documents:
The correlation between uptake of uranium by the blood and urinary uranium concen tration is shown in Figure 9 for Class (D) materials.
  ICRP Publication 30, "Limits for Intakes of Radionuclides by Workers" (Ref. 1 1),  ICRP Publication 60, "Recommendations of the International Commission on Radiological Protection" (Ref. 1 2),    ICRP Publication 66, "Human Respiratory Tract Model for Radiological Protection
" (Ref. 1 3),  ICRP Publication 68, "Dose Coefficients for Intakes of Radionuclides by Workers" (Ref.


1 4),   ICRP Publication 71, "Age-Dependent Doses to Members of the Public from Intake of Radionuclides-Part 4 Inhalation Dose Coefficients" (Ref. 1 5),    IAEA Safety Guide RS
Recommended actions, from Table 5, are indicated.
-G-1.2, "Assessment of Occupational Exposure due to Intake of Radionuclides" (Ref. 1
6), and  International Organization for Standardization (ISO/IEC) 17025, "General requirements for the competence of testing and calibration laboratories" (Ref.


17). The ISO/IEC 17025 specifies the general requirements for the competence to carry out tests and/or calibrations, including sampling. It covers consensus testing and calibration methods for QA.
8.11-8 TABLE 4 ACTION DUE TO BIOASSAY MEASUREMENT
RESULTS, RADIATION
DOSE Result < 1/5 MPDca Contamination confinement and air sampling capabilities are confirmed.


The NRC encourages licensees to consult these and other international documents and implement good practices, where applicable, that are consistent with NRC regulations. It should be noted that some of the recommendations issued by these international organizations do not correspond to the requirements specified in the NRC's regulations. In all cases, the NRC's requirements take precedence.
No action required.


Documents Discussed in Staff Regulatory Guidance This regulatory guide endorses, in part, the use of one or more codes or standards developed by external organizations, and other third party guidance documents.
1/5 < Result < 1/2 MPDc Contamination confinement and/or air sampling capabilities are marginal.


These codes, standards and third party guidance documents may contain references to other codes, standards or third party guidance documents ("secondary references").
If a result in this range was expected because of past experience or a known incident, any corrective action to be taken presumably has been or is being accomplished;
If a secondary reference has itself been incorporated by reference into NRC regulations as a requirement, then licensees and applicants must comply with that standard as set forth in the regulation.
no action is required by the bioassay result. If the result was unexpected: (I) Confirm result (air sample data review, comparison with other bioassay data, additional bioassay measurements).
(2) Identify probable cause and, if necessary, correct or initiate additional control measures.


If the secondary reference has been endorsed in a regulatory guide as an acceptable RG 8.11, Rev. 1, Page
(3) Determine whether others could have been exposed and perform bioassay measurements for them. (4) If exposure (indicated by excreta analysis)
5  approach for meeting an NRC requirement, then the standard constitutes a method acceptable to the NRC staff for meeting that regulatory requirement as described in the specific regulatory guide.
could have been to Class (W) or Class (Y) dust, consider the perfor mance of diagnostic in vivo measurements.


If the secondary reference has neither been incorporated by reference into NRC regulations nor endorsed in a regulatory guide, then the secondary reference is neither a legally
1/2 < Result < 1 MPDc Contamination confinement and/or air sampling capabilities are unreliable unless a result in this range was expected because of a known unusual cause, in such cases, corrective action in the work area presumably has been or is being taken, and action due to the bioassay result includes action (7) only. Conditions under which a result in this range would be routinely expected are undesirable.
-binding requirement nor a "generic" NRC approved acceptable approach for meeting an NRC requirement. However, licensees and applicants may consider and use the information in the secondary reference, if appropriately justified , consistent with current regulatory practice, and consistent with applicable NRC requirements.


C.  STAFF REGULATORY GUIDANC
If the result was due to such conditions or was actually unexpected, take actions (1) through (4) and: (5) If exposure (indicated by excreta analysis)
E  The NRC staff considers certain sections of ANSI/HPS N13.22
could have been to Class (W) or Class (Y) dust, assure that diagnostic in vivo measurements are performed.
-2013, "Bioassay Programs for Uranium," acceptable for use as stated in the staff regulatory positions listed below.


1. Participation Criteria Licensees should ensure that the appropriate individuals are assigned on a scheduled basis (e.g., quarterly) to submit specimens for bioassay or to report for in
(6) Review the air sampling program, determine why air samples were not representative and make necessary corrections.
-vivo measurements in the bioassay program. Decisions about which individuals should participate in bioassay programs should be based on the criteria described below:
  a. individuals who could receive certain dose s as stated in 10 CFR 20.1502(a)
or (b);    b. individuals who work with uranium or who are close enough to the chemical process using uranium that exposure and intake is possible (e.g., within a few meters and in the same room as the worker handling the radioactive material); or c. individuals described in Section 5 ("Selection of Individuals for Bioassay") of ANSI/HPS N13.22-2013 and individuals who work under the specified conditions listed in Table 1 ("Implementation Levels: Mass or Activity Levels Above Which at Least Minimum Uranium Bioassay Program Shall be Implemented") of ANSI/HPS N13.22
-2013.    2. Conditions under which Bioassay Should Be Performed Licensees should ensure that bioassays are performed for appropriate conditions. Section 3 ("Establishing the Need for an Internal Dosimetry Program") of ANSI/HPS N13.22
-2013 describes acceptable conditions under which a uranium bioassay should be performed.    3. Types of Bioassay Monitoring that Should Be Performed Licensees should ensure that the types of monitoring implemented by the bioassay program are appropriate for the types of material present at the licensee's facility. For example, inhaled materials of different lung classes will likely call for different monitoring techniques. The procedures and methods described in ANSI/HPS N13.22
-2013 are considered acceptable for selecting and implementing the appropriate monitoring techniques
.    4. Bioassay Frequency In any particular facility, the frequency of bioassays should be based on estimates of the type and quantity of intakes that are likely to occur during the monitoring year.


RG 8.11, Rev. 1, Page
(7) Perform additional bioassay measurements as necessary to make a preliminary estimate of the critical organ burden; consider work limitations to ensure that the MPDc is not exceeded.
6  The bioassay frequencies for routine sampling, as well as for bioassays in other situations, that are described in Section 4.2 ("Frequencies") of ANS/HPS N13.22
-2013, are acceptable. If special circumstances exist at the licensee's facility, a submittal should be provided to NRC for review and assessment of the proposed frequencies. Table 8 of ANSI/HPS N13.22
-2013 prescribes the minimum frequencies of bioassays that are acceptable. Section 4.2.2 ("Other Frequency Situations") of ANSI/HPS N13.22-2013 describes those situations where it may be necessary to sample more frequently than is indicated in Table
8.


5. Action Levels and the Associated Actions
(8) If exposure could have been to Class (Y) dust, bring expert opinion to bear on cause of exposure, and continue operations only if it is virtually certain that the limit of I MPDc will not be exceeded by any worker. Result > I MPDc Contamination confinement and/or air sampling capabilities are not acceptable, unless a result of this magnitude was expected because of a known unusual cause: in such cases, corrective action in the work area presumably has been ov is being taken, and action due to the bioassay result includes actions (10) and (11) only. Prevalent conditions under which a result in this range would be expected are not acceptable.


Licensees should ensure that the appropriate actions are taken based on bioassay results. The action levels for bioassay that are listed in Table 2 ("Urinalysis Action Levels") and Table
If the result was due to such conditions or was actually unexpected, take actions(I)  
7 ("Action Levels for Special Class Y Uranium") and described in Section
through (7) and: (9) Take action (8), regardless of dust classification.
6 ("Action Levels and Follow
-up Actions") of ANSI/HPS
N13.22-2013 are acceptable. However, where exposure conditions and the characteristics of the materials differ significantly from those recommended in the ANSI standard, the licensee may modify the derivation of the action levels to conform to local conditions at the facility.


6. Limiting Chemical Toxicity and Work Restrictions Soluble uranium is a Class D or Type F aerosol as defined in ICRP Publications 30 and 66 , respectively, based on the retention time in the pulmonary region. The NRC regulation, 10 CFR 20.120 1(e) requires that licensees limit the soluble uranium intake by an individual to
(10) Establish work restrictions as necessary for affected employees.
10 milligrams in a week in consideration of chemical toxicity, which may cause damage to the kidneys.  Paragraph 20.120
1(e) also directs licensees to footnote 3 of appendix B of 10 CFR part 20; footnote 3 concerns soluble mixtures of U
-234, U-235 and U-238 in air. Licensees should develop the required procedures to prevent soluble uranium exposures from exceeding this non
-radiological limit.


7. Bioassay Interpretation Licensees should ensure that bioassay data is interpreted to estimate intakes and doses using the retention and excretion data. RG
(11) Perform individual case studies (bioassays)  
8.9, Section 4 ("Interpretation of Bioassay Measurements"), or in NUREG/CR-4884, "Interpretation of Bioassay Measurements," provide guidance on bioassay interpretation.
for affected employees.


In addition, commercial software is available for bioassay interpretations and internal dose calculations. For NRC staff to accept the calculations developed by such software, the assumptions relied upon by the licensee, including the conditions of the uranium and sampling information associated with the bioassay result
aThe annual MPDC is a 50-yr integrated dose of 15 rems to the lung or 30 reins to the bone.8.11-9 TABLE 5 ACTION DUE TO BIOASSAY MEASUREMENT
, should be presented to NRC. The licensee should demonstrate the accuracy of its assumptions (i.e., by verification and validation).
RESULTS, CHEMICAL TOXICITY Result < 1/2 L4 Contamination confinement and air sampling capabilities are adequate.
    8. Uranium Air Concentrations Licensees should ensure that uranium concentration in air is appropriately determined. Methods for airborne uranium surveillance and for determining uranium air concentrations are described in


RG 8.25, "Air Sampling in the Workplace" and in RG 8.30, "Health Physics Surveys in Uranium Recovery Facilities."  The guidance in RG 8.22, "Bioassay at Uranium Mills," may also be applicable depending on involvement of uranium materials at the licensee's facility.
No action required.


RG 8.11, Rev. 1, Page
1/2 L < Result < L Contamination confinement and/or air sampling capabilities do not provide an adequate margin of safety. If a result in this range was expected because of past experience or a known incident, any corrective action to be taken presumably has been or is being accomplished;
7  9.     Quality Assurance (QA)  The "Quality Assurance" procedures of licensee bioassay programs that satisfy the requirements of the ASME standard NQA
no action is required by the bioassay result. If the result was unexpected:
-1-19 94, "Quality Assurance Program Requirements for Nuclear Facilities (with Addenda)"
(1) Confirm result (air sample data review, comparison with other bioassay data, additional bioassay measurements).
will be deemed acceptable to the NRC staff. The reference to this ASME standard is also included in RG
(2) Identify probable cause and, if necessary, correct or initiate additional control measures.
4.15, "Quality Assurance for Radiological Monitoring Programs (Inception through Normal Operations to License Termination
)-Effluent Streams and the Environment" and in ANSI/HPS N13.22-2013, Section 7, "Quality Assurance and Control."
10. Reports and Notifications to the NRC and Exposed Individual If an overexposure occurs, licensees are subject to the NRC incident reporting requirements in  10 CFR 20.2203 and 20.2205. Licensees should be familiar with these reporting requirements.


==D. IMPLEMENTATION==
(3) Determine whether others could have been exposed and perform bioassay measurements for them.  (4) Determine why the bioassay result was not predicted by the air sampling program and make necessary corrections.
The purpose of this section is to provide information on how licensees may use this RG. In addition, it describes how the NRC staff complies with the backfitting provisions in 10
CFR 70.76(a)(1).    Use by Licensees Licensees may voluntarily use the guidance in this RG to demonstrate compliance with the underlying NRC regulations.


Methods or solutions that differ from those described in this RG may be deemed acceptable if they provide sufficient basis and information for the NRC staff to verify that the proposed alternative demonstrates compliance with the appropriate NRC regulations. Current licensees (i.e., persons holding a NRC issued license as of the date of issuance of this RG) may continue to use guidance the NRC found acceptable for complying with the identified regulations as long as their current licensing basis remains unchanged. The acceptable guidance may be from the previous version of this RG. Licensees may use the information in this RG for actions which do not require NRC review and approval. Licensees may also use the information in this RG to resolve regulatory or inspection issues.
(5) Consider work limitations to ensure that L is not exceeded.


Use by NRC Staff The NRC staff does not intend or approve any imposition or backfitting of the guidance in this RG. The NRC staff does not expect any current licensee to use or commit to using the guidance in this RG, unless such licensee makes a change to its licensing basis. The NRC staff does not expect or plan to initiate NRC regulatory action that would require the use of this RG. Examples of such regulatory actions include the issuance of an order or generic communication, or the promulgation of a rule
(6) If bioassay result was near L, bring expert opinion to bear on cause of exposure, and continue operations only if it is virtually certain that L will not be exceeded by any worker.  Result > L Contaminatiow confinement and/or air sampling capabilities are not acceptable, unless a result of this magnitude was expected because of a known unusual cause; in such cases, corrective actuon in the work area presumably has been or is being taken, and action due to the bioassay result includes actions (7) and (8) only. Prevalent conditions under which a result in this range would be expected are not acceptable.
, requiring the use of this RG without further backfit consideration.


During regulatory discussions on licensee
If the result was due to such conditions or was actually unexpected, take actions ( I ) through (6) and: (7) Establish work restrictions as necessary for affected employees.
-specific operational issues, the NRC staff may discuss with licensees various actions consistent with staff positions in this RG, as one acceptable means of meeting the underlying NRC
regulatory requirement s. Such discussions would not ordinarily be considered backfitting
, even if prior versions of this RG are part of the licensee's licensing basis. However, unless this RG is part of the licensee's licensing basis, the staff may not represent to the licensee that the licensee's failure to comply with the positions in this RG constitutes a violation.


If a current licensee voluntarily seeks a license amendment or change and (1) the NRC staff's consideration of the request involves a regulatory issue directly relevant to this RG and (2) the specific subject matter of this RG is an essential consideration in the staff's determination of the acceptability of the licensee's request, then the staff may request that the licensee either follow the guidance in this RG 8.11, Rev. 1, Page
(8) Have additional urine specimen tested for albuminuria under direction of a physician.
8  regulatory guide or provide an equivalent alternative process that demonstrates compliance with the underlying NRC regulatory requirements.


Such a request by the NRC staff is not considered backfitting as defined in 10 CFR 70.76(a)(1).
aL is 2.7 ing of uranium in the bWood. Assume uptake is 43% of intake.(2) Class (D) Dust, Dual Action Requirements If the urinary uranium concentration is suf ficiently large, action due to both radiation dose and chemical toxicity may be necessary.
  If a licensee believes that the NRC is either using this RG or requesting or requiring the licensee to implement the methods or processes in this RG in a manner inconsistent with the discussion in this Implementation section, then the licensee may file a backfit appeal with the NRC in accordance with the guidance in NRC Management Directive 8.4, "Management of Facility
-Specific Backfitting and Information Collection"
(Ref. 18) and NUREG-1409, "Backfitting Guidelines" (Ref. 19).       
RG 8.11, Rev. 1, Page
9  REFERENCES
1  1. Title 10 of the Code of Federal Regulations, (10 CFR), part 70, "Domestic Licensing of Special Nuclear Material." U.S.


Nuclear Regulatory Commission (NRC), Washington, DC.
Both Figures 8 and 10 should be consulted for this determination.


2. 10 CFR part
Figure I I presents values of specific activity acceptable for con verting activity to gravimetric units. For exposure to multiple enrichments, values from Figure 11 should be weighted to obtain an appropriate specific activity.
20, "Standards for Protection against Radiation." NRC, Washington, DC.


3. NRC, Regulatory Guide (RG) 8.9, "Acceptable Concepts, Models, Equations, and Assumptions for a Bioassay Program." NRC, Washington, DC.
If the weighting factors are unknown, the smallest specific activity present shou!d be used.(3) Dose Commitment Correlation, Single Intake, Class (W) and Class (Y) Dust, Excreta Analysis The correlation between dose commitment to the lung, urinary uranium concentration, and uraniuirn fecal excretion rate is shown in Figures 12 through 14 for Class (W) and Class (Y) materials.


4. NRC, RG 8.22, "Bioassay at Uranium Mills." NRC, Washington, DC.
Recommended actions, from Table 4, are indicated.


5. NRC, RG 8.25, "Air Sampling in the Workplace." NRC, Washington, DC.
(4) Dose Commitment Correlation, Single Intake, Clan (W) and Class (Y) Dust, In Vivo The correlation between dose commitment to the lung and the mass of U-235 measured in the thorax 8.11-10 I
by in vivo techniques is shown in Figure 15 for Class (W) materials and in Figure 16 for Class (Y) materials.


6. NRC, RG 8.30, "Health Physics Surveys in Uranium Recovery Facilities." NRC, Washington, DC.    7. NRC, RG 4.15, "Quality Assurance for Radiological Monitoring Programs (Inception through Normal Operations to License Termination)
Recommended actions, from Table 4, are indicated.
- Effluent Streams and the Environment." NRC, Washington, DC.


8. National Council on Radiation Protection and Measurements (NCRP) Report 161, "Management of Persons Contaminated with Radionuclides." National Council on Radiation Protection and Measurements, Bethesda, MD, 2008.2  9. NUREG/CR-4884, "Interpretation of Bioassay Measurement." NRC, Washington, DC.
These figures are applicable to uranium of 20 w/o U-235; scaling factors are provided in Figure 17 for other enrichments.


10. American National Standards Institute
(5) Exposure to Mixtures If a positive urinalysis specimen is obtained following exposure to a mixture that included significant quantities of Class (Y) materials, actions (1) through (11) in Table 4 should be taken. if the exposure was to a mixture of Class (W) dust and-Class (D) dust with chemical toxicity limiting, the urinary uranium mass concentration should be determined and the curves in Figure 9 used to determine the required actions from Table 5; the activity concen tration should also be determined, using Figure 12 with Table 4.  If exposure was to a mixture of Class (W) dust and Class (D) dust with bone dose limiting, it is necessary to estimate the fraction of the dust inhaled that was Class (W), fw, and the fraction that was Class (D), fd. It is also necessary to determine the urinary excretion factors, Ew and Ed, that would be applicable at the timie the specimen was obtained;
/Health Physics Society Standard, N13.22
Figure 18 may be used for this purpose. If R represents the bioassay result in pCi/day, Rd the Class (D) component and Rw the Class (W) component, such that R = Rd + Rw, then Rd = fdEdR/(fdEd
-2013, "Bioassay Programs for Uranium." American National Standards Institute: Health Physics Society, McLean, VA.3 11. International Commission on Radiological Protection (ICRP) Publication 30, "Limits for Intakes of Radionuclides by Workers:  Part 1." International Commission on Radiological Protection, Pergamon Press, Oxford, England, 1979.
+ fwEw) aw = fwEwR/(fdEd
+ fwEw) These results should be converted to concentra tion using the factor 1.4 I/day. Then the curves in Figure 8 or Figure 12 should be used to determine the required actions from Table 4If positive in vivo results are obtained following exposure to a mixture of Class (W) and Class (Y) materials, Figure 16 should be used to determine the required actions from Table 4. (6) Lung Burden Correlations, Continuous Intake In some working areas airborne uranium is routinely present and is responsible for the chronic appearance of uranium in urine. Continuous intakes of this nature may also be responsible for chronically positive in vivo measurement results. Under these condi tions positive bioassay results are expected, and the monitonng tasks are to measure the lung burden buildup and to identify single intake peaks above this expected level. Thus it is evident that for purposes of exposure control the chronic levels due to continuous intake do not alter the approach outlined for the detection of single intakes.


4                                         
The correlation between in vivo measurements of U-235 and lung burden is shown in Figure 19. In.vivo measurements are considered to be much more reliable than urinalysis for Class (W) and Class (Y) materials.
    1  Publicly available NRC
-published documents are available online through the NRC Library on the NRC's public Web site at http://www.nrc.gov/reading
-rm/doc-collections/. The documents can also be viewed online or printed for a fee in the NRC's Public Document Room (PDR) at 11555 Rockville Pike, Rockville, MD; the mailing address is USNRC PDR, Washington, DC 20555; telephone 301
-415-4737 or (800) 397
-4209; fax (301) 415
-3548; and e-mail pdr.resource@nrc.gov
.  2  Copies of the National Council on Radiation Protection and Measurements documents may be obtained through the organization's Web site:  http://www.ncrponline.org/Publications/Publications.html] or by writing to NCRP at 7910 Woodmont Avenue, Suite 400, Bethesda, MD  20814
-3095, telephone 301
-657-2652, fax: 301
-907-8768.  3  Copies of American National Standards Institute documents may be purchased through their Web site at: http://webstore.ansi.org/
.  4  Copies of the International Commission on Radiological Protection (ICRP) documents may be obtained through the organization's Web site: http://www.icrp.org/
or by writing to ICRP at 280 Slater Street, Ottawa, Ontario  K1P 5S9, CANADA, telephone +1(613) 947
-9750, fax: +1(613) 944
-1920.


RG 8.11, Rev. 1, Page
However, urinalysis may be used to indicate that in vivo measurements are promptly needed. rThe average value from several urinalysis results (R) can be used with Figure 20 to estimate the number of maximum per missible lung burdens (MPLB = 0.016 pCi). Arrange ments for in vivo measurements should be undertaken when AR is found to exceed 0.5. If &#xfd;'R >1, additional exposure should be avoided until in vivo results are available.
10  12. ICRP Publication 60, "Recommendations of the International Commission on Radiological Protection." ICRP, Pergamon Press, Oxford, England , 1991. 13. ICRP Publication 66, Human Respiratory Tract Model for Radiological Protection , 1 st Edition, Pergamon Press, Oxford, England, 1994.


14. ICRP Publication 68, "Dose Coefficients for Intakes of Radionuclides by Workers." ICRP, Pergamon Press, Oxford, England, 1994.
(7) Referral to a Physician When confirmed bioassay measurement results indicate that the Maximum Permissible Annual Dose (MPAD) to the lung or bone has been or will be exceeded by a factor of 2, the affected individual should be so informed, and referral to a physician knowledge able in the biological effects of radiation and conversant in the nature and purpose of regulatory dose limits should be considered.


15. ICRP Publication 71, "Age-Dependent Doses to Members of the Public from Intake of Radionuclides
When confirmed bioassay results indicate that an exposure to uranium has resulted in an uptake by the blood of more than 2.7 mg within 7 consecutive days or less, the affected individual should be informed of his exposure and referred to a physician knowledgeable in the chemical effects of internally administered uranium.
-Part 4 Inhalation Dose Coefficients." ICRP, Pergamon Press, Oxford, England, 1995.  16. IAEA, Safety Guide No. RS
-G-1.2, "Assessment of Occupational Exposure due to Intake of Radionuclides." International Atomic Energy Agency, Safety Standards Series, Vienna.1999.


5  17. International Organization for Standardization (ISO/IEC) 17025:2005, "General requirements for the competence of testing and calibration laboratories." International Organization for Standardization, Geneva, Switzerland. 2005.
(8) Work Restrictions AEC regulations establish an upper limit on exposures during a specified period of time; it follows that work restrictions may be necessary to prevent exposures from exceeding this limit. Such restrictions may also be necessary to prevent the deposition of uranium in the body in such quantity that: (i) the mass of uranium entering the blood will exceed 2.7 mg in 7 consecutive days; (ii) the activity present in the lung will pro duce an annual dose-equivalent to the pulmonary region exceeding
15 reins; (iii) the activity present in the bone will produce an annual dose-equivalent to the bone exceeding
30 reins.  For personnel who have a body burden of uranium that is producing an annual dose-equivalent greater than 15 rems to the pulmonary region of the lung or 30 reins to the bone or both, work restrictions
8.111-11 may be imposed as necessary to assure that the additional radiation dose from sources under the control of the employer would be considered negligible by a qualified health physicist.


6 http://www.iso.org/iso/Catalogue_detail?csnumber=39883
4. Diagnostic Guidance In previous sections a monitoring program has been described which should detect every instance of serious deposition of uranium in the body. Once a deposition of this nature has been identified, the bioassay purpose changes from exposure control to diagnosis.
.  18. NRC Management Directive 8.4, "Management of Facility
-Specific Backfitting and Information Collection." NRC, Washington, DC.


19. NUREG-1409, "Backfitting Guidelines." NRC, Washington, DC
With respect to chemical toxicity, the objective is to determine whether the uranium uptake was sufficient to cause kidney damage. The radiological objectives are to esti mate (1) the quantity of uranium present in the organ of reference, (2) the rate of elimination, (3) the magnitude of the original deposition, and (4) the dose commitment.


5  Copies of International Atomic Energy Agency (IAEA) documents may be obtained through their Web site at: http://www.iaea.org or by writing the International Atomic Energy Agency P.O. Box 100 Wagramer Strasse 5, A
As with exposure control monitoring, use of models is necessary.
-1400 Vienna, Austria. Telephone (+431) 2600
-0, Fax (+431) 2600
-7, or E-Mail at Official.Mail@IAEA.org.


Copies of International Organization for Standardization (ISO) documents may be obtained through their Web site at:
However, it is usually possible in a given individual's case to use factual data rather than some of the assumptions, and every opportunity for such refine ment .should be taken. This subject is treated in considerab!e detail in WASH-1251, Section V.8.11-12 I
http://www.iso.org or by writing the International Central Secretariat, 1, c
A4R SAMPLING DATA NOT REPRESENTATIVE
I REPRESENTATIVE
1 -QTR. AVE,_<10%
DAC 1 -QTR. AVE.>10% DAC MAXIMUM_<
25% DAC MAXIMUM >25% DAC USE OF NON-REPRESENTATIVE
AIR SAMPLING DATA IS NOT ACCEPTABLE
IN DETERMINING
THE 1 -QTR. AVE.[MINIMUM BIOASSAY PROGRAM]SADDITIONAL
BIOASSAYS
I Figure 1 Criteria for Initiating Additional Bioassays, Routine Conditions Figure 2 Criteria for Diagnostic Bioassays Durings Special Investigations
8.1 1-13
~i2 LU z wig laj 010 100 101 102 10310 MEASUREMENT
SENSITIVITY
LIMIT (pCi/I) Figure 3 Maximumn Time Between Specimens to Detect 1 MPDc, Class (D) Uranium Dust, w/o U-235 >80
3 1 1I I I TI l I1 I1111 " V! IIIT _ S102 u -USE FIGURE 11 TO CONVERT TO ACTIVITY UNITS.  wI 9- 0 uJ 101 -100 I I -11111 I X 111 1 I 1 11111 I I I I III1 10-1 100 101 102 103 104 MEASUREMENT
SENSITIVITY
LIMIT (pg/I) Figure 4 Maximum Time Between Specimens to Detect Uptake of 2.7 mg Class (D) Uranium, w/o U-235:580 ,
6 .I-12..z Lu z UA 2 uj 100 , I 1 1 1 Hill I 101 102 MEASUREMENT
SENSITIVITY
Lo3 LIMIT (pCi/I)10 10 I I I I I III I I I ( iiY) CLASS (Y)q_I I I I I Iif I I 10-1 100 101 MEASUREMENT
SENSITIVITY
LIMIT (pCi/I)Figure 5 Maximum Time Between Specimens to Detect 1 MPDc, Class (W) or Class (Y) Uranium VI A L= a ..... ........103 4 0 WJ 2 I I 1 1111 i I I 1111U I I 111111 I I I 11111 20 w/o U-235 93% U-235 I ! I III_III', I. I 4 6-.z Ln U. 2 I-z Lu Lu U.1 cn w uz t-.101 I I I IIIll I I I IIIII I I 1 11111 I I I I I lll 102 103 MEASUREMENT
SENSITIVITY
LIMIT (pg U-235)Figure 6 Maximum Time Between Measurements to Detect 1 MPDc In Vivo, Class (W)--I I'j--4 102 .-I,, I I I I I III 1001 10 0 w-- -I I -- .. ....... ...... .....II 1 1 1 1 1 1 C IV i TIME BETWEEN MEASUREMENTS (DAYS) 0 ._ ---F c m "os m Zm 00 m a *
103~~~~~~~ --,,t,/ 3ris1M~ TABLE LL .7 ... ....... ....... ....... 'w mm C N 0 2 6 rams I- / RESU w 10"0 0 N( 10-21 1 ItI I I l 1 100 101 102 103 URINARY URANIUM CONCENTRATION (pCi/I) Figure 8 Dose Commitment Indicated by Model vs. Urinary Uranium Concentration, Class (D), Single Intake 8.11-19
104I 1 I I 1 1 1II I l I I I 103 E -j ,o 2 S10 a 100 0 U CL100 AI 10.1 ........ .. .. / .. I 10- 100 101 102 URINARY URANIUM CONCENTRATION (pg/I) Figure 9 Uptake in Blood Indicated by Model vs. Urinary Uranium Concentration, Class (D), Single Intake 8.11-20
102. I 1 I 1 S101 zA wA -Z 10 RESULTS LEFT OF BAND REQUIRE NO ACTION.  RESULTS WITHIN BAND REQUIRE ACTIONS (1) THRU (6), TABLE 5 RESULTS RIGHT OF BAND REQUIRE ACTIONS (1) THRU (8), TABLE 5 10"1 __ 1_ 1 1 !1_ 1 _ _11111_ 1 I I 111111 I I 1 111i 1 10-1 100 101 102 103 104 URINARY URANIUM CONCENTRATION (pCi/I) Figure 10 Action Guide for Urinalysis Results Following Single Intake of Uranium, Chemical Toxicity
10.4 -- I 1 0 S =(0.4 + 0.38E + 0.0034E 2) 10-6 00 K 0_ _ 00 I L) 0 Al DATA < 0 GULF DATA U.o IAEA SS NO. 6 uli A ORO-651 EQUATIOF S10-6 S (U-dep) 3.6 x 10-7 Ci/gm 0 20 40 60 80 100 WITHOUT U-235, E Figure 11 Specific Activity for Mixtures of U-238, U-234 and U-235 8.11-22 I .
1I III I I ...CLASS (Y) ol* o* 102 4 V RE -J U..  I-ACTIC 15 reins =I MPDc TAL io 1 /2 < F 0 101 .5 rtms -ACTI 0;- ......................
...... ............
!...........
elm S-- __ 1/5<R UU ACTIO lo- 000 S~REE 10-1 100 101 102 103 URINARY URANIUM CONCENTRATION (pCi/l) Figure 12 Dose Conmmitment Indicated by Model vs. Urinary Uranium Concentration, Class (W) and (Y), Single Intake 8.11-23
1 0 2 1 R E S U L T >1 M P Oc 00 10ACTIONS
(1) THRU 11) 15 em TABLE 4 oQ .........
... ..........
... I........
.......  0 1/2 e RESULT S1I MPD, 2 1O, ACTIONS (11) THRU W( 0= ... .............. ..........
.. ..........  cc -1/5 < RESULT S1 /2 MPO, LL -ACTIONS (1) T44RU 14) A; RESULT -1 /5 MPDC 0 100 Lkl ! NO ACTION 0 a 10-2 1 1 1 .1 1 l 1 100 101 102 103 URANIUM FECAL EXCRETION
RATE (pCi/DAY)
Figure 13 Dose Commitment Indicated by Model vs. Uranium Fecal Excretion Rate, Class (W), Single Intake L 8.11-24 ,C03.


====h. de la Voie====
102 REI ACT 10 TABLI 0........................................a~*
-Creuse, CP 56, CH
000 0:ass.. .................
-1211 Geneva 20, Switzerland. Telephone (+41) 22 749 01 11, Fax (+41) 22 733 34 30, or E-Mail at Central@ISO.org.}}
Noennn 1 1/2< F 10. ACTIC _, ........ .........s............u
,. ....................
,.. _ 1/6< R ACTIO 2 100 2 0 10-1 100 101 102 103 URANIUM FECAL EXCRETION
RATE (pCi/DAY)
Figure 14 Doss Commitment Indicated by Model Vs. Uranium Fecal Excretion Raft, Class (Y), Single Intake 8.11-25
104 S20 w/o U-235 15-ein.1 PDCT" 0 101 120 35 reins IM A 1/ tN y!yo (p U-235) Figure 15 Dose Commitment Indicated by Model vs. In Vivo Result, Cless (W), Single Intake 3. 11-26
10 4 10 102oooe)mlm olao o mla e ao m 20 w/o U-235A Is rams 1 MPD, 7.5 rin 1 ..~ ....... .................
ag RESULT r1/5 MPD, NO ACTION 104 IN VIVO RESULT (pg U-235) ,Figure 16 Don Commitment Indicated by Model vs. In Vivo Result, Class (Y), Single Intake 8.11-27 RESULT >1 MPOc ACTIONS (1) THRU 111) TABLE 4 1/2- RESULTS!_I
MPD&#xa2; ACTIONS (1) THRU 68) 1f5 <RESULTS1I2 MPO, ACTIONS (1) THRU (4)0 0 0 U.  I 2)102 101 100 10"1 101 103 A t 11 I.5 -,/-ii_40 50 60 w/o U-235 Figure 17 fmiichiment Scaling Factors for Model Dose Commitment Curves, In ViyD Measurement Following Single Exposure to Class (Wl or Class (Y) Uranium Dust 90 100 711 0 z o0 00J 1.2 1.1 1.0 U EU A U!I I I r I t zu 30 70 80
-10'4 0 10-4 z 10 100 1011013 TIME (DAYS AFTER INTAKE) Figure 18 Urinary Uranium Excretion Factors for Determining RD and Rw 8.11-29 LO) 200 100 -l 1 1 L 1 L L 1 I 0 10 20 30 40 50 60 70 80 90 w/o U-235 FIGURE 19 Equilibrium Mass of U-235 in the Lung Equivalent to 1 Ma, n rrn Permissible Lung Burden 100
102 1111 1 11I1!111 I IuI I I I 1 101 100 0. w a. IL 10-11 101 102 103 104 TIME AFTER BEGINNING
OF EXPOSURE (DAYS) Figure 20 Model for Interpreting Urinalysis Results During Continuous Exposure to Constant Concentration of Uranium in Air 8,11-31}}


{{RG-Nav}}
{{RG-Nav}}

Revision as of 02:58, 21 September 2018

Applications of Bioassay for Uranium
ML003739450
Person / Time
Issue date: 06/30/1974
From:
Office of Nuclear Regulatory Research
To:
References
RG-8.11
Download: ML003739450 (31)


A. INTRODUCTION

Section 20.108, "Orders Requiring Furnishing of Bioassay Services," of 10 CFR Part 20, "Standards for Protection Against Radiation," states that the Atomic Energy Commission may incorporate in any license provisions requiring bioassay measurements as necessary or desirable to aid in determining the extent of an individual's exposure to concentrations of radioactive material.

As used by the Commission, the term bioassay includes in vivo measurements as well as measurements of radioactive material in excreta. This guide provides criteria acceptable to the Regulatory staff for the development and implementation of a bioassay program for mixtures of the naturally occurring isotopes of uranium U-234, U-235, and U-238. The guide is programmatic in nature and does not deal with labora tory techniques and procedures.

Uranium may enter the body through inhalation or ingestion, by absorption through normal skin, and through lesions in the skin. However, inhalation is by far the most prevalent mode of entry for occupational exposure.

The bioassay pro gram described in this guide is applicable to thi inhalation of uranium and its compounds, but does not include the more highly transportable compounds UF 6 and U0 2 F 2. Significant features of the bioassay program devel oped in this guidb ar listed below: 1. A bioassay program is necessary if air sampling is necessary for purposes of personnel protection.

The extent of the bioassay program is determined by the magnitude of air sample results.

2. A work area qualifies for the "minimum bioassay program" so long as the quarterly average of air sample results is <1% of the Derived Air Concentration (DAC) and the maximum used to obtain the average is <25% of USAEC REGULATORY

GUIDES Regulatory Guides we issued to describe and make available to the public rnelhods acceptable to ite AEC Regulatory staff of impmenmeting specific parts of the Cominrnstion's regulations, to delineate lechniques, -ed by the Staff in Ielliusting specific problems or postulated accidents.

or to provide guidance to aplitants Reglatory Guides ore not substitutes for regulations and complianci with them is not required.

Methods and solutions different from thoKi at set nm the guidlsl will be acscaptable if they provide a basts for the findings requisite to the iesuance or continuance of a permit or by the Commission.

Published will be revised periodicalt-.i at apropr~ate, to accommodatei commnrs amtd to relfle new information or experience.

June 1974 GUIDE DAC. It must be demonstrated that air sample results used for this purpose are representative of personnel exposure.

3. Under the minimum program, bioassays are per formed semiannually or annually for all workers to monitor the accumulatiorý

of uranium in the lung and bone. More frequent bioassays are performed for a sample of the most highly exposed workers as a check on the air sampling program; these bioassays are per formed at sufficient frequency to assure that a signifi cant single intake of uranium will be identified before biological elimination of the uranium renders the intake undetectable.

4. If a work area does not qualify for the minimum program, bioassays in addition to the minimum program are performed at increasingly higher frequencies, de pending on the magnitude of air sample results.

5. A model is used which correlates bioassay measure ment results with radiation .dose or with uptake of uranium in the blood (chemical toxicity).

6. Actions are specified, depending upon the dose or uptake indicated by bioassay results. These actions are corrective in nature and are intended to ensure adequate worker protection.

7. Guidance is referenced for the difficult task of determining, from individual data rather than models, the quantity of uranium in body organs, the rate of elimination, and the dose commitment.

This bioassay program encourages improvement in the confinement of uranium and in air, sampling tech niques by specifying bioassays only to-ihe extent that confinement and air sampling can not be entirely relied upon for personnel protection.

C*0vPp of piutiishedguidtosmay be obtained by requet indicating the divisions testirend to the US. Atomic Energy Condmmd.on Washington D.C. Attention.

Director of Regulatory Stan<erde.

Comments and sugestions for irorsrovesents in t hes guides ae encouraged and Should be sent to the Secretary of the Commetuon, US. Atomic Energv Commission Wahington, D.C. 20545. Attention:

Chief Public Proceedings Staff. The uide* are issued in the following ten broad divisions:

1. Power Reactors 6. Products 2. A emrch and Test Reactors

7. Transportation

3. Fuels med Materials Facilities

8.

Health 4. Enronmental and Siting 9, Antitrust Review S. Meegesair and Plant Protection

10. General U.S. ATOMIC ENERGY COMMISSION

REGULATORY

DIRECTORATE

OF REGULATORY

STANDARDS

REGULATORY

GUIDE 8.11 APPLICATIONS

OF BIOASSAY FOR URANIUM

B. DISCUSSION

The topics treated in this guide include determining

(1) whether bioassay procedures are necessary, (2) which bioassay techniques to use and how often, (3) who should participate, (4) the action to take as based on bioassay results, and (5) the particular results which should initiate such action. Taken together, these topics comprise an exposure control program. Technical bases for the criteria appearing in the guide are provided in "Applications of Bioassay for Uranium," WASH-1251, which is available from the Superintendent of Docu ments, U.S. Government Printing Office, Washington, D.C. 20402. After an exposure to uranium has occuired, the difficult problems of estimating the quantity present in the body and the anticipated dose commitment arise. This subject is treated in considerable detail in WASH 1251. C. REGULATORY

POSITION !. Special Terminology Several of the terms used in this guide have been given special definitions and are listed in this section for the convenience of the reader. Bioassay -The determination of the kind, quantity or concentration, and location of radioactive material in the human body by direct (in vivo) measurement or by analysis of materials excreted or removed from the body. Derived Air Concentration (DAC) -- Equivalent to the concentrations listed in Appendix B to 10 CFR Part 20. Dowe Commitment (Dc) -- The total radiation dose equivalent to the body or specified part of the body that will be received from an intake of radioactive material during the 50-year period following the intake. Exposure -The product of the average concentration of radioactive material in air and the period of time during which an individual was exposed to that average concentration (jICi-hr/cc).

Intake -The quantity of radioactive material entenng the nose and/or mouth during inhalation;

the product of the exposure and the breathing rate. In Vivo Measurements

-Measurement of gamma or X-radiation emitted from radioactive material located within the body, for the purpose of estimating the quantity of radioactive material present.Maximum Permissible Annual Dose (MPAD) The annual maximum occupational radiation dose recommended by the ICRP for the body or part ul' the body. Maximum Permissible Dose Commitment (MPDc) A dose commitment numerically equivalent to the Maximum Permissible Annual Dose. Measurement Sensitivity Limit The smallest quan tity or concentration of radioactive material that can be measured with a specified degree of accuracy and precision.

Nontransportable- Slowly removed from the pul monary region of the lung by gradual dissolution .in extracellular fluids, or in particulate form by translocation to the GI tract, blood, or lymphatic system; Class (W), nontransportable dust with 50-day biological half-life in the lung. Class (Y), nontransportable dust with 500-day biological half-life in the lung. Transportable- Dissolved upon contact with extra cellular fluids and translocated to the blood- Class (D), transportable dust with rapid clearance from the lung. Uptake -- The quantity of radioactive material enter ing the nose and/or mouth during inhalation that is not exhaled and enters extracellular fluids. w/o U-235 Percentage by weight of the isotope U-235 in a mixture of U--234, U-235, and U-238 (w/o U-235 in natural uranium is 0.72). 2. Programmatic Guidance The following programmatic guides are applicable where personnel are occupationally exposed to uranium in respirable form and in sufficient quantity that measurements of uranium concentrations in air are considered to be necessary for the protection of workers in ccmpliance with Regulatory requirements, including license conditions.

a. Basic Requirements and Minimum Capabilities The following guides establish basic requirements and minimum capabilities which should he found in a program for protection against internal exposure from operations with uranium: (1) Responsibilities foi protection against ura nium contamination should be weil defined and under stood by all personnel concerned and should be specified in direct;ves from management

(2) A comprehensive and technically sound protec tion program should be developed and implemented.

8.11-2 L I

(3) Personnel, space, equipment, and support resources should be provided as necessary to conduct the program.

(4) An effective method of periodic internal audit of the protection program should be maintained.

(5) Before assigning employees to work in an area where exposure to uranium contamination may occur, action should be taken to ensure that facility and equipment safeguards necessary for adequate radiation protection are present and operable, that the employees are properly trained, that adequate procedures are prepared and approved, that an adequate surface and air contamination survey capability exists, that a bioassay program at least equivalent to the program described in this guide will be maintained, and that survey and bioassay records will be kept. b. Bioassay Program In the development of a bioassay program the following guides should be implemented:

(1) Necessity The determination of the need for bioassay measurements should be based on air contamination monitoring results in accordance with criteria contained in this guide. (2) Preparatory Evaluation Before assigning an employee to work in an area where substantial exposure to uranium contami nants may occur, his condition with respect to radio active material of similar chemical behavior previously deposited and retained in his body should be determined and the necessity for work restrictions evaluated.

(3) Exposure Control The bioassay program should include, as appro priate, capabilities for excreta analyses and in vivo measurements, made separately or in combination at a sufficiently high frequency to assure that engineered confinement and air and surface contamination surveys are adequate for employee protection.

The program should include all potentially exposed employees.

(4) Diagnostic Evaluation The bioassay program should include capabili ties for excreta analyses and in vivo measurements as necessary to estimate the quantity of uranium deposited in the body and/or in affected organs and the rate of elimination from the body and/or affected organs.3. Operational Guidance a. Criteria for Determining the Need for a Bioasay Program Where air sampling is required for purposes of occupational exposure control, bioassay measurements are also needed (Table 1) The bioassay frequency should be determined by air sample results as averaged over I quarter.

Testing should be performed to determine whether awi sampling is representative of personnel exposures.

Air sample results which have been verified as representative may be used to determine the quarterly average.

If the 1-quarter average does not exceed 10% of the appropriate Derived Air Concentration (DAC) from Appendix B to 10 CFR Part 20 and if the maximum result used in the calculation of the average does not exceed 25% of DAC, only a minimum bioassay program is necessary (Table 2). If the 1-quarter average exceeds 10% DAC, or if the maximum result exceeds 25% of the DAC, additional bioassays are necessary (Table 3), except as noted below. Frequency criteria for both cases are discussed in Section C.3.c. The approach is illus trated in Figure 1. The additional bioassays are not performed for a specific individual if the licensee can demonstrate that the air sampling system used to protect the individual is adequate to detect any significant intake- and that procedures exist for diagnostic bioassays following detection of an apparently large intake. The necessity for bioassay measurements may also arise following an incident such as a fire, spill, equip ment malfunction, or other departure from normal operations which caused, or could have caused, abnor mally high concentrations of uranium An air. Criteria for determining this necessity are shown in Pigure 2. (The term "Early Information" refers to an instrumented air sampler with an alarm device.) Reliance cannot be placed on nasal swab results from mouth breathers.

bioassays should be performed.

Special bioassay measurements should be per formed to evaluate the effectiveness of respiratory protection devices. If an individual wearing a respiratory protection device is subjected to a concentration of transportable uranium in air within a period of I week, such that his exposure with no respiratory protection device would have exceeded 40 x DAC ,Ci-hr/cc, urinalysis should be performed to determine the result ing actual uranium uptake. If an individual wearing a 8.11-3 TABLE I SELECTION

OF BIOASSAY MEASUREMENT

TECHNIOUES

Transportable Non transportable Purpose Compounds Compounds Choice of Measurement

1st 2nd' 3rd Preparatory Evaluationb uc ivc fr u Exposure Control Check on Air Sampling Program u iv f u Monitoring of Lung Burden Buildup -iv f u Monitoring of Bone Burden Buildup u u Detection of Unsuspected Intake u iv f Diagnostic Evaluation u iv f u Work Restriction Removal i iv f u alf for any reason air sampling is not adequately effective, and the appearance of urinary uranium is long delayed by extreme nontransportability, the buildup of uranium in the lung pmay continue undetected until a positive in vivo result is obtained.

Fecal analysis is an excellent and highly recommended early indicator in such cases. Fecal analysis should be considered if in vivo measurements are too infrequent to permit early identification of an unfavorable trend. bDiagnostic evaluation necessary if results are positive.

Cu, urinalysis;

f, fecal analysis;

iv. in vivo.respiratory protection device is subjected to a concen tration of nontranrsportable uranium in air within a period of 13 weeks, such that his exposure with no respiratory protection device would have exceeded 520 x DAC jiCi-hr/cc, the resulting actual uranium deposition in the lung should be determined using in vivo measurements and/or fecal analyses.

These special bioassay procedures should also be conducted if for any reason the magnitude of the exposure (with no respira tory protection device) is unknown.

b. Selection of Measurement Techniques The appropriate selection of bioassay techniques appears in Table 1. Preparatory evaluation refers to bioassays performed for job applicants or existing employees prior to an assignment involving potential exposure to uranium. Exposure control refers to bio assays performed to assure that engineered confinement and the air sampling program are sufficiently effective in the control and evaluation of exposures.

Diagnostic evaluation refers to bioassays performed following a known significant exposure.

These evaluations are per formed to determine the location and magnitude of uranium deposition, which would in turn aid in deter mining whether therapeutic procedures are indicated and whether work restrictions are necessary.

The evaluations would also aid in estimating the retention function and dose commitment.

Work restriction removal refers to bioassays performed for employees who, because of past depositions of radionuclides, have been restricted by management in their work involving exposure to radio active material until the magnitude of such depositions is reduced sufficiently to permit the removal of these work restrictions.

c. Selection of Measurement Frequency Acceptable frequencies for the minimum bioassay program are given in Table 24Table 3 gives acceptable frequencies when additianal bioassay measurements are necessary to detect unsuspected single intakes, unless the measurement capability is the limiting factor. Figures 3 through 7 present the maximum time between measure ments based on measurement sensitivity considerations;

the figures should be used to determine the measure ment frequency unless the interval specified in Table 3 is shorter. The Class (W) curve in Figure 5 may be used for Class (Y) materials if it is known that Class (D) or Class (W) materials are present.

Table 2 specifies, for the minimum program, semiannual or annual bioassays for monitoring the accumulation of uranium in the lung and bone, plus 8.11-4 TABLE 2 BIOASSAY FREQUENCY

FOR EXPOSURE CONTROL Program Objective Dust Measurement Frequency Classification Techniquea Check on air sampling (D) u Use Figures 3 and 4 program and on con- (W) iv Use Figure 6 finement procedures (Y) iv Semiannual Minimum" and equipment.

Adequate if Monitor lung burden (W) iv AnnualF QA < I/ I 0DA( buildup. (Y) iv Serruannualc and M < 1/4 DAC Monitor bone burden (D) u Semiannual buildup. (W) u Semiannual (Y) u Class (D) or Class (W) Not Present, Annuald (Y) u Class (D) or Class (W) Present, Semiannuald Additional Detect unsuspected (D) u Use Table 3e intake. (W) iv, f, or u Use Table 3 e Acceptable it (Y) iv, f. or u Use Table 3e QA > 1/10 DAC and/or M > 1/4 DAC aiv, n vivo; u, urinalysis;

f, fecal analysis.

bQA, quarterly average of air sample results; M, maximum result used to determine QA CThese frequencies are applicable if no individuals are near work restriction limits. Quarterly or even monthly iv may become necessary as workers approach these limits dSpecial urinalysis should be performed each time exposure to new Class (Y) material begins to determine if more transportable component is present.

eThese measurements are additional to those listed above for the minimum program. If it is demonstrated that air sampling provided for a specific individual is adequate to detect any sigmficant intake and that procedures exist for diagnostic bioassays following detection of an apparently large intake, these additional measurements need not be performed.

(00

TABLE 3 FAEQUENCYa FOR ADDITIONAL

BIOASSAYS

BASED ON CONCENTRATION

OR EXPOSURE QA Most recent quarterly average of concentration or most recent quarterly average of weekly exposures M Maximum result used in the calculation of the quarterly average u urinalysis iv -it vivo Multiply numbers in first column by DAC pCi/cc or by 40 DAC pCi-hr/cc.

Frequencies are given in bioassaysper year at equally spaced intervals.

Air Sample Results Class (D) Class(W) u U iv Class (Y) ub iv O<QA< 1/10 1/4<M< I I <M< 10 10<M I/i0<QA< 1/4 0<M< I I <M<10 10< M 1/4<QA< 1/2 C<M< I i<M< !0 ii < M 4 12 4 12 2c 4 12 12 26 1i2<QA< I 0<M< 10 10<M 2 4 12 2 4 12 4 12 26 26 52 1 2 4 1 2 4 2 4 12 12 12 2 4 12 4 12 26 12 26 52 26 52 2 2 4 4 4 4 4 12 12 12 a Low frcqucncicý

indicated may be precluded by measurement capability limitations:

see Figures 3 through 7 bAppicable if Class (D) or Class (W) materials are known to be present;convert

52 and 26 to 12 if they are not present. Fecal analysis may be substituted for urinalysis.

c Frequency possible only for high w/o U-235; naturally occurring urinary uranium prohibits detection otherwise.

more frequent bioassays (based on measurement sensi tivity) to check on the air sampling program. Section C.3.d indicates that all workers should participate in the bioassay program for purposes of monitoring the organ buildup, while only a sample of workers is sufficient for checking the air sampling program. If a working area does not qualify for the minimum program, additional bioassays are specified in Table 3 at somewhat higher frequencies.

Any urinalysis procedure performed for one of these purposes may be used to satisfy a urinalysis requirement for another purpose, provided the fre quency criteria are met. A similar statement may be made regarding in vivo measurements.

The purpose of the additional bioassay measure ments is the timely detection of unsuspected exposures not detected by the air sampling program. Therefore, the additional bioassays are not necessary for an individual who is protected by a monitoring system that essentially assures detection of any significant intake. Although fecal analysis is not shown in Table 3, this procedure is preferred over urinalysis for Class (W) and Class (Y) materials and may be substituted for urinalysis in the table. If in vivo measurements are made at the frequency shown for urinalysis, Class (W) and Class (Y), the unnalyses are unnecessary;

the urinalyses prescribed in Table 2 are adequate.

The bioassay measurement frequency, as deter mined from Table 2 or 3 (or the associated figures), should not be decreased because of consistently low bioassay results; bioassay measurements are needed as a final check on the contamination confinement capability and on the effectiveness of the air sampling program.

Consistently high bioassay results may suggest that more 8.11-6 frequent bioassays should be performed even though there is no such indication from air samples. In this case, however, improvements in the air sampling program are required rather than more frequent bioassays.

The appropriate frequency can be determined from air sample data if the air sampling program is adequately representative of inhalation exposures.

If workers are exposed to a mixture of uranium compounds, the DAC for the mixture, DACm, should be calculated as Dn= [i, f DACm Zi DAC 1]-I where DACi is the DAC for the ith compound and fi is a fraction representing the contribution of the ith com pound. The calculation of fi depends on the exposure mode. If the material is a mixture, fi is the activity fraction.

For exposure in more than one area, fi is the time fraction spent in the ith area. As an alternative DACm may be taken as the lowest DACi. As to the quarterly average for air samples, if the material is a mixture and exposure occurs in only one area, the quarterly average calculation, applicable to all workers in the area, should be performed as for non-mixtures, i.e., from samples characterizing conditions in the area. If exposures occur in several areas, the quarterly average for the mixture may be a time-weighted average for the individual, using ( arterly average air samples that characterize full-time conditions in each area. i.e., n QAm = 2 fi QAi i=l where QAi is the quarterly average for the ith area and fi is the time fraction of the quarter that the individual worked in the ith area. As an alternative, QAm may be taken as the highest QAi. Figure 5 indicates that a urinalysis measurement sensitivity of about 0.7 pCi/I is required to detect the equivalent of I MPDc following a single exposure to Class (Y) materials with neither Class (D) nor Class (W) "'tracer" dusts present. To obtain this sensitivity, a chemical concentration procedure is necessary.

Fecal analysis is recommended as an alternative, using the frequency schedule given for urinalysis.

If work restrictions that have been imposed do not involve total exclusion from restricted areas, it is necessary to ensure that bioassay measurements made for the purpose of removing work restrictions are performed at least as frequently as would be required for purposes of exposure control.A monthly in vivo frequency may be reduced to quarterly if weekly fecal analyses are made, with an in vivo measurement at the end of the quarter. An in vivo measurement should be performed as soon as practicable if the excretion rate exceeds 7 pCi/day Class (Y) or 700 pCi/day Class (W). For lower results the following procedure should be followed.

Results from the first 4 weekly specimens should be plotted (semilog)

against time, and a best fitting curve should be extrapolated to t = 0. thus obtaining an estimate of the initial excretion rate, (dP Idt)o, and the individual's half-lifel T. The dose commitment, Dc, should be estimated using these values with the following equation: Dc= 8.4 T2 [where T is in days and (dP/dt)o is in MOCt/day.

The actions indicated in Table 4 should then be taken. This procedure should be repeated at the end of 8 weeks when results from 8 specimens are available.

At the end of the quarter D. should be evaluated using results from all 12 specimens.

If the indicated Dc is < 3 rems, the in vivo measurement may be considered unnecessary If the Dc indicated by the fecal data exceeds 3 reins, the in vivo measurement should be performed.

A quarterly in vivo frequency may be reduced to semiannual if monthly fecal analyses are made, with an in vivo measurement at the end of 6 months If any result exceeds 7 pCi/day Class (Y) or 460 pCi/day Class (W). an in vivo measurement should be performed as soon as practicable.

For lower results the following procedure should be followed.

Results from the first 3 specimens should be plotted (semilog)

against time, and a best-fitting straight line should be extrapolated to t= 0. Values for (dP /dt)o and T for the individual should be obtained and used in the above equation to estimate Dc. The actions indicated in Table 4 should then be taken. At the end of the fourth and fifth month, Dc should again be evaluated using results from all specimens.

At the end of the 6-month period, the in vivo measurement should be performed.

Fecal specimens used for this purpose should be obtained after 2 or more days of no exposure.

In the extrapolation of excretion rate data to t= 0. it is necessary to ignore data points obtained for less than 2 days after exposure.

d. Participation All personnel whose regular iob assignmentN

involve work in an area where bioassay ineasurernenI,, are required should participate in the bioassay program However, as long as air sainple results qualify the area and group of workers tor the minimum bioasssa program, special consideration may be given in the case 8.1 1-7 of bioassays obtained for the purpose of checking on the air sampling program, i.e., the first objective shown in Table 2. For these bioassays it is acceptable to limit participation to a representative sample of the group. The sample should be composed of the most highly exposed or potentially exposed personnel and should include at least 10% of the workers who have regular job assignments in the area if the total number of such workers is 100 or more. If the total is between 100 and 10 workers, there should be 10 participants.

If the total is less than 10 workers, all should participate.

Thus, where the minimum bioassay program is being con ducted, all workers would participate either semi annually or annually for monitoring of uranium buildup in the lung or bone, in addition, those in the sample group would participate more frequently if required to do so by Figures 3, 4, or 6. (Note that the in vivo frequency for Class (Y) materials is semiannual in every case.) This sampling procedure will be of particular usefulness to those using Figure 4. Where bioassays in addition to the minimum program are conducted, all workers should participate (see Table 2, footnote e, for exception).

Personnel whose duties involve only observance and who spend less than 25% of the work week in areas where bioassay is required may participate on a limited basis. The interval between bioassay measurements for such personnel should be a matter of judgement based on the magnitude of the exposure.

e. Action Based on Results Appropriate action as based on bioassay results is dependent first on the underlying purpose of the measurement.

(!) Preparatory Evaluation Where urinalysis for uranium is used to screen personnel prior to job assignment, the presence of any urinary uranium, as detected by routine laboratory procedures, should trigger an investigation.

Information regarding the location and quantity of uranium in the body should be sought, and conservative predictions as td future retention in the body should be made. This information can usually be derived from a review of the worker's previous exposure history, including previous bioassay results, and from subsequent bioassay measure mrents as necessary.

Findings should be compared with criteria given in Section C.3.f.(8), or with other accept able criteria, and a decision should be made to approve the job assignment if acceptable criteria are met, or to impose a delay otherwise.

(2) Exposure Control When work is in progress, and bioassay mea surements are being made routinely, it is essential to ensure that the measurement results are carefully reviewed by qualified personnel and that appropriate action is taken if the results are considered high. Action should be based on the organ burden, the dose commit ment, or chemical damage to the kidney as indicated (however roughly) by the result. Appropriate actions are shown in Tables 4 and 5 for single intakes. In the case of chronic exposure, when bioassay results indicate that the organ burden is continuing to rise, action should be taken to assure that additional buildup will not interfere with the worker's career. When urinalysis indicates

50% or more of the maximum permissible lung burden for nontransportable uranium, in vivo measurements should be undertaken.

Work restrictions should be tmposed without waiting for in vivo measurements if urinalysis indicates more than I permissible lung burden. (3) Diagnostic Evaluation Diagnostic bioassay measurements are made to .estimate the quantity and distribution of radionuclides in the body after determination that a large deposition has occurred.

Actions to be based on diagnostic results include (I) selection of subsequent measurement tech niques and frequencies, (2) imposition or removal of work restrictions, (3) referral to a physician, and (4) the physician's decision to attempt acceleration of the nuclide elimination process.

f. Action Points This -section presents acceptable correlations be tween organ burden, dose commitment, or uranium uptake and the quantities actually measured using bioassay techniques, thus providing action point criteria for purposes of exposure control. Guidance is also given for work restrictions and for referral to a physician.

These correlations are derived entirely from models. This approach is acceptable for purposes of exposure control. However, these correlations would actually predict the dose commitment or uranium uptake only if the bioassay result was without error and if every condition of the models was actually achieved.

(1) Dose Commitment and Uptake Correiations, Single Intake, Class (D) Dust The correlation between dose commitment to the bone and urinary uranium concentration is shown in Figure 8 for Class (D) materials.

In the right hand margin of the figure the recommended actions, from Table 4, are indicated.

The correlation between uptake of uranium by the blood and urinary uranium concen tration is shown in Figure 9 for Class (D) materials.

Recommended actions, from Table 5, are indicated.

8.11-8 TABLE 4 ACTION DUE TO BIOASSAY MEASUREMENT

RESULTS, RADIATION

DOSE Result < 1/5 MPDca Contamination confinement and air sampling capabilities are confirmed.

No action required.

1/5 < Result < 1/2 MPDc Contamination confinement and/or air sampling capabilities are marginal.

If a result in this range was expected because of past experience or a known incident, any corrective action to be taken presumably has been or is being accomplished;

no action is required by the bioassay result. If the result was unexpected: (I) Confirm result (air sample data review, comparison with other bioassay data, additional bioassay measurements).

(2) Identify probable cause and, if necessary, correct or initiate additional control measures.

(3) Determine whether others could have been exposed and perform bioassay measurements for them. (4) If exposure (indicated by excreta analysis)

could have been to Class (W) or Class (Y) dust, consider the perfor mance of diagnostic in vivo measurements.

1/2 < Result < 1 MPDc Contamination confinement and/or air sampling capabilities are unreliable unless a result in this range was expected because of a known unusual cause, in such cases, corrective action in the work area presumably has been or is being taken, and action due to the bioassay result includes action (7) only. Conditions under which a result in this range would be routinely expected are undesirable.

If the result was due to such conditions or was actually unexpected, take actions (1) through (4) and: (5) If exposure (indicated by excreta analysis)

could have been to Class (W) or Class (Y) dust, assure that diagnostic in vivo measurements are performed.

(6) Review the air sampling program, determine why air samples were not representative and make necessary corrections.

(7) Perform additional bioassay measurements as necessary to make a preliminary estimate of the critical organ burden; consider work limitations to ensure that the MPDc is not exceeded.

(8) If exposure could have been to Class (Y) dust, bring expert opinion to bear on cause of exposure, and continue operations only if it is virtually certain that the limit of I MPDc will not be exceeded by any worker. Result > I MPDc Contamination confinement and/or air sampling capabilities are not acceptable, unless a result of this magnitude was expected because of a known unusual cause: in such cases, corrective action in the work area presumably has been ov is being taken, and action due to the bioassay result includes actions (10) and (11) only. Prevalent conditions under which a result in this range would be expected are not acceptable.

If the result was due to such conditions or was actually unexpected, take actions(I)

through (7) and: (9) Take action (8), regardless of dust classification.

(10) Establish work restrictions as necessary for affected employees.

(11) Perform individual case studies (bioassays)

for affected employees.

aThe annual MPDC is a 50-yr integrated dose of 15 rems to the lung or 30 reins to the bone.8.11-9 TABLE 5 ACTION DUE TO BIOASSAY MEASUREMENT

RESULTS, CHEMICAL TOXICITY Result < 1/2 L4 Contamination confinement and air sampling capabilities are adequate.

No action required.

1/2 L < Result < L Contamination confinement and/or air sampling capabilities do not provide an adequate margin of safety. If a result in this range was expected because of past experience or a known incident, any corrective action to be taken presumably has been or is being accomplished;

no action is required by the bioassay result. If the result was unexpected:

(1) Confirm result (air sample data review, comparison with other bioassay data, additional bioassay measurements).

(2) Identify probable cause and, if necessary, correct or initiate additional control measures.

(3) Determine whether others could have been exposed and perform bioassay measurements for them. (4) Determine why the bioassay result was not predicted by the air sampling program and make necessary corrections.

(5) Consider work limitations to ensure that L is not exceeded.

(6) If bioassay result was near L, bring expert opinion to bear on cause of exposure, and continue operations only if it is virtually certain that L will not be exceeded by any worker. Result > L Contaminatiow confinement and/or air sampling capabilities are not acceptable, unless a result of this magnitude was expected because of a known unusual cause; in such cases, corrective actuon in the work area presumably has been or is being taken, and action due to the bioassay result includes actions (7) and (8) only. Prevalent conditions under which a result in this range would be expected are not acceptable.

If the result was due to such conditions or was actually unexpected, take actions ( I ) through (6) and: (7) Establish work restrictions as necessary for affected employees.

(8) Have additional urine specimen tested for albuminuria under direction of a physician.

aL is 2.7 ing of uranium in the bWood. Assume uptake is 43% of intake.(2) Class (D) Dust, Dual Action Requirements If the urinary uranium concentration is suf ficiently large, action due to both radiation dose and chemical toxicity may be necessary.

Both Figures 8 and 10 should be consulted for this determination.

Figure I I presents values of specific activity acceptable for con verting activity to gravimetric units. For exposure to multiple enrichments, values from Figure 11 should be weighted to obtain an appropriate specific activity.

If the weighting factors are unknown, the smallest specific activity present shou!d be used.(3) Dose Commitment Correlation, Single Intake, Class (W) and Class (Y) Dust, Excreta Analysis The correlation between dose commitment to the lung, urinary uranium concentration, and uraniuirn fecal excretion rate is shown in Figures 12 through 14 for Class (W) and Class (Y) materials.

Recommended actions, from Table 4, are indicated.

(4) Dose Commitment Correlation, Single Intake, Clan (W) and Class (Y) Dust, In Vivo The correlation between dose commitment to the lung and the mass of U-235 measured in the thorax 8.11-10 I

by in vivo techniques is shown in Figure 15 for Class (W) materials and in Figure 16 for Class (Y) materials.

Recommended actions, from Table 4, are indicated.

These figures are applicable to uranium of 20 w/o U-235; scaling factors are provided in Figure 17 for other enrichments.

(5) Exposure to Mixtures If a positive urinalysis specimen is obtained following exposure to a mixture that included significant quantities of Class (Y) materials, actions (1) through (11) in Table 4 should be taken. if the exposure was to a mixture of Class (W) dust and-Class (D) dust with chemical toxicity limiting, the urinary uranium mass concentration should be determined and the curves in Figure 9 used to determine the required actions from Table 5; the activity concen tration should also be determined, using Figure 12 with Table 4. If exposure was to a mixture of Class (W) dust and Class (D) dust with bone dose limiting, it is necessary to estimate the fraction of the dust inhaled that was Class (W), fw, and the fraction that was Class (D), fd. It is also necessary to determine the urinary excretion factors, Ew and Ed, that would be applicable at the timie the specimen was obtained;

Figure 18 may be used for this purpose. If R represents the bioassay result in pCi/day, Rd the Class (D) component and Rw the Class (W) component, such that R = Rd + Rw, then Rd = fdEdR/(fdEd

+ fwEw) aw = fwEwR/(fdEd

+ fwEw) These results should be converted to concentra tion using the factor 1.4 I/day. Then the curves in Figure 8 or Figure 12 should be used to determine the required actions from Table 4. If positive in vivo results are obtained following exposure to a mixture of Class (W) and Class (Y) materials, Figure 16 should be used to determine the required actions from Table 4. (6) Lung Burden Correlations, Continuous Intake In some working areas airborne uranium is routinely present and is responsible for the chronic appearance of uranium in urine. Continuous intakes of this nature may also be responsible for chronically positive in vivo measurement results. Under these condi tions positive bioassay results are expected, and the monitonng tasks are to measure the lung burden buildup and to identify single intake peaks above this expected level. Thus it is evident that for purposes of exposure control the chronic levels due to continuous intake do not alter the approach outlined for the detection of single intakes.

The correlation between in vivo measurements of U-235 and lung burden is shown in Figure 19. In.vivo measurements are considered to be much more reliable than urinalysis for Class (W) and Class (Y) materials.

However, urinalysis may be used to indicate that in vivo measurements are promptly needed. rThe average value from several urinalysis results (R) can be used with Figure 20 to estimate the number of maximum per missible lung burdens (MPLB = 0.016 pCi). Arrange ments for in vivo measurements should be undertaken when AR is found to exceed 0.5. If ý'R >1, additional exposure should be avoided until in vivo results are available.

(7) Referral to a Physician When confirmed bioassay measurement results indicate that the Maximum Permissible Annual Dose (MPAD) to the lung or bone has been or will be exceeded by a factor of 2, the affected individual should be so informed, and referral to a physician knowledge able in the biological effects of radiation and conversant in the nature and purpose of regulatory dose limits should be considered.

When confirmed bioassay results indicate that an exposure to uranium has resulted in an uptake by the blood of more than 2.7 mg within 7 consecutive days or less, the affected individual should be informed of his exposure and referred to a physician knowledgeable in the chemical effects of internally administered uranium.

(8) Work Restrictions AEC regulations establish an upper limit on exposures during a specified period of time; it follows that work restrictions may be necessary to prevent exposures from exceeding this limit. Such restrictions may also be necessary to prevent the deposition of uranium in the body in such quantity that: (i) the mass of uranium entering the blood will exceed 2.7 mg in 7 consecutive days; (ii) the activity present in the lung will pro duce an annual dose-equivalent to the pulmonary region exceeding

15 reins; (iii) the activity present in the bone will produce an annual dose-equivalent to the bone exceeding

30 reins. For personnel who have a body burden of uranium that is producing an annual dose-equivalent greater than 15 rems to the pulmonary region of the lung or 30 reins to the bone or both, work restrictions

8.111-11 may be imposed as necessary to assure that the additional radiation dose from sources under the control of the employer would be considered negligible by a qualified health physicist.

4. Diagnostic Guidance In previous sections a monitoring program has been described which should detect every instance of serious deposition of uranium in the body. Once a deposition of this nature has been identified, the bioassay purpose changes from exposure control to diagnosis.

With respect to chemical toxicity, the objective is to determine whether the uranium uptake was sufficient to cause kidney damage. The radiological objectives are to esti mate (1) the quantity of uranium present in the organ of reference, (2) the rate of elimination, (3) the magnitude of the original deposition, and (4) the dose commitment.

As with exposure control monitoring, use of models is necessary.

However, it is usually possible in a given individual's case to use factual data rather than some of the assumptions, and every opportunity for such refine ment .should be taken. This subject is treated in considerab!e detail in WASH-1251,Section V.8.11-12 I

A4R SAMPLING DATA NOT REPRESENTATIVE

I REPRESENTATIVE

1 -QTR. AVE,_<10%

DAC 1 -QTR. AVE.>10% DAC MAXIMUM_<

25% DAC MAXIMUM >25% DAC USE OF NON-REPRESENTATIVE

AIR SAMPLING DATA IS NOT ACCEPTABLE

IN DETERMINING

THE 1 -QTR. AVE.[MINIMUM BIOASSAY PROGRAM]SADDITIONAL

BIOASSAYS

I Figure 1 Criteria for Initiating Additional Bioassays, Routine Conditions Figure 2 Criteria for Diagnostic Bioassays Durings Special Investigations

8.1 1-13

~i2 LU z wig laj 010 100 101 102 10310 MEASUREMENT

SENSITIVITY

LIMIT (pCi/I) Figure 3 Maximumn Time Between Specimens to Detect 1 MPDc, Class (D) Uranium Dust, w/o U-235 >80

3 1 1I I I TI l I1 I1111 " V! IIIT _ S102 u -USE FIGURE 11 TO CONVERT TO ACTIVITY UNITS. wI 9- 0 uJ 101 -100 I I -11111 I X 111 1 I 1 11111 I I I I III1 10-1 100 101 102 103 104 MEASUREMENT

SENSITIVITY

LIMIT (pg/I) Figure 4 Maximum Time Between Specimens to Detect Uptake of 2.7 mg Class (D) Uranium, w/o U-235:580 ,

6 .I-12..z Lu z UA 2 uj 100 , I 1 1 1 Hill I 101 102 MEASUREMENT

SENSITIVITY

Lo3 LIMIT (pCi/I)10 10 I I I I I III I I I ( iiY) CLASS (Y)q_I I I I I Iif I I 10-1 100 101 MEASUREMENT

SENSITIVITY

LIMIT (pCi/I)Figure 5 Maximum Time Between Specimens to Detect 1 MPDc, Class (W) or Class (Y) Uranium VI A L= a ..... ........103 4 0 WJ 2 I I 1 1111 i I I 1111U I I 111111 I I I 11111 20 w/o U-235 93% U-235 I ! I III_III', I. I 4 6-.z Ln U. 2 I-z Lu Lu U.1 cn w uz t-.101 I I I IIIll I I I IIIII I I 1 11111 I I I I I lll 102 103 MEASUREMENT

SENSITIVITY

LIMIT (pg U-235)Figure 6 Maximum Time Between Measurements to Detect 1 MPDc In Vivo, Class (W)--I I'j--4 102 .-I,, I I I I I III 1001 10 0 w-- -I I -- .. ....... ...... .....II 1 1 1 1 1 1 C IV i TIME BETWEEN MEASUREMENTS (DAYS) 0 ._ ---F c m "os m Zm 00 m a *

103~~~~~~~ --,,t,/ 3ris1M~ TABLE LL .7 ... ....... ....... ....... 'w mm C N 0 2 6 rams I- / RESU w 10"0 0 N( 10-21 1 ItI I I l 1 100 101 102 103 URINARY URANIUM CONCENTRATION (pCi/I) Figure 8 Dose Commitment Indicated by Model vs. Urinary Uranium Concentration, Class (D), Single Intake 8.11-19

104I 1 I I 1 1 1II I l I I I 103 E -j ,o 2 S10 a 100 0 U CL100 AI 10.1 ........ .. .. / .. I 10- 100 101 102 URINARY URANIUM CONCENTRATION (pg/I) Figure 9 Uptake in Blood Indicated by Model vs. Urinary Uranium Concentration, Class (D), Single Intake 8.11-20

102. I 1 I 1 S101 zA wA -Z 10 RESULTS LEFT OF BAND REQUIRE NO ACTION. RESULTS WITHIN BAND REQUIRE ACTIONS (1) THRU (6), TABLE 5 RESULTS RIGHT OF BAND REQUIRE ACTIONS (1) THRU (8), TABLE 5 10"1 __ 1_ 1 1 !1_ 1 _ _11111_ 1 I I 111111 I I 1 111i 1 10-1 100 101 102 103 104 URINARY URANIUM CONCENTRATION (pCi/I) Figure 10 Action Guide for Urinalysis Results Following Single Intake of Uranium, Chemical Toxicity

10.4 -- I 1 0 S =(0.4 + 0.38E + 0.0034E 2) 10-6 00 K 0_ _ 00 I L) 0 Al DATA < 0 GULF DATA U.o IAEA SS NO. 6 uli A ORO-651 EQUATIOF S10-6 S (U-dep) 3.6 x 10-7 Ci/gm 0 20 40 60 80 100 WITHOUT U-235, E Figure 11 Specific Activity for Mixtures of U-238, U-234 and U-235 8.11-22 I .

1I III I I ...CLASS (Y) ol* o* 102 4 V RE -J U.. I-ACTIC 15 reins =I MPDc TAL io 1 /2 < F 0 101 .5 rtms -ACTI 0;- ......................

...... ............

!...........

elm S-- __ 1/5<R UU ACTIO lo- 000 S~REE 10-1 100 101 102 103 URINARY URANIUM CONCENTRATION (pCi/l) Figure 12 Dose Conmmitment Indicated by Model vs. Urinary Uranium Concentration, Class (W) and (Y), Single Intake 8.11-23

1 0 2 1 R E S U L T >1 M P Oc 00 10ACTIONS

(1) THRU 11) 15 em TABLE 4 oQ .........

... ..........

... I........

....... 0 1/2 e RESULT S1I MPD, 2 1O, ACTIONS (11) THRU W( 0= ... .............. ..........

.. .......... cc -1/5 < RESULT S1 /2 MPO, LL -ACTIONS (1) T44RU 14) A; RESULT -1 /5 MPDC 0 100 Lkl ! NO ACTION 0 a 10-2 1 1 1 .1 1 l 1 100 101 102 103 URANIUM FECAL EXCRETION

RATE (pCi/DAY)

Figure 13 Dose Commitment Indicated by Model vs. Uranium Fecal Excretion Rate, Class (W), Single Intake L 8.11-24 ,C03.

102 REI ACT 10 TABLI 0........................................a~*

000 0:ass.. .................

Noennn 1 1/2< F 10. ACTIC _, ........ .........s............u

,. ....................

,.. _ 1/6< R ACTIO 2 100 2 0 10-1 100 101 102 103 URANIUM FECAL EXCRETION

RATE (pCi/DAY)

Figure 14 Doss Commitment Indicated by Model Vs. Uranium Fecal Excretion Raft, Class (Y), Single Intake 8.11-25

104 S20 w/o U-235 15-ein.1 PDCT" 0 101 120 35 reins IM A 1/ tN y!yo (p U-235) Figure 15 Dose Commitment Indicated by Model vs. In Vivo Result, Cless (W), Single Intake 3. 11-26

10 4 10 102oooe)mlm olao o mla e ao m 20 w/o U-235A Is rams 1 MPD, 7.5 rin 1 ..~ ....... .................

ag RESULT r1/5 MPD, NO ACTION 104 IN VIVO RESULT (pg U-235) ,Figure 16 Don Commitment Indicated by Model vs. In Vivo Result, Class (Y), Single Intake 8.11-27 RESULT >1 MPOc ACTIONS (1) THRU 111) TABLE 4 1/2- RESULTS!_I

MPD¢ ACTIONS (1) THRU 68) 1f5 <RESULTS1I2 MPO, ACTIONS (1) THRU (4)0 0 0 U. I 2)102 101 100 10"1 101 103 A t 11 I.5 -,/-ii_40 50 60 w/o U-235 Figure 17 fmiichiment Scaling Factors for Model Dose Commitment Curves, In ViyD Measurement Following Single Exposure to Class (Wl or Class (Y) Uranium Dust 90 100 711 0 z o0 00J 1.2 1.1 1.0 U EU A U!I I I r I t zu 30 70 80

-10'4 0 10-4 z 10 100 1011013 TIME (DAYS AFTER INTAKE) Figure 18 Urinary Uranium Excretion Factors for Determining RD and Rw 8.11-29 LO) 200 100 -l 1 1 L 1 L L 1 I 0 10 20 30 40 50 60 70 80 90 w/o U-235 FIGURE 19 Equilibrium Mass of U-235 in the Lung Equivalent to 1 Ma, n rrn Permissible Lung Burden 100

102 1111 1 11I1!111 I IuI I I I 1 101 100 0. w a. IL 10-11 101 102 103 104 TIME AFTER BEGINNING

OF EXPOSURE (DAYS) Figure 20 Model for Interpreting Urinalysis Results During Continuous Exposure to Constant Concentration of Uranium in Air 8,11-31